Encyclopedias as Topic: Works containing information articles on subjects in every field of knowledge, usually arranged in alphabetical order, or a similar work limited to a special field or subject. (From The ALA Glossary of Library and Information Science, 1983)Angiogenesis Inhibitors: Agents and endogenous substances that antagonize or inhibit the development of new blood vessels.Endostatins: Angiostatic proteins that are formed from proteolytic cleavage of COLLAGEN TYPE XVIII.Neovascularization, Pathologic: A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions.MedlinePlus: NATIONAL LIBRARY OF MEDICINE service for health professionals and consumers. It links extensive information from the National Institutes of Health and other reviewed sources of information on specific diseases and conditions.Bacteria: One of the three domains of life (the others being Eukarya and ARCHAEA), also called Eubacteria. They are unicellular prokaryotic microorganisms which generally possess rigid cell walls, multiply by cell division, and exhibit three principal forms: round or coccal, rodlike or bacillary, and spiral or spirochetal. Bacteria can be classified by their response to OXYGEN: aerobic, anaerobic, or facultatively anaerobic; by the mode by which they obtain their energy: chemotrophy (via chemical reaction) or PHOTOTROPHY (via light reaction); for chemotrophs by their source of chemical energy: CHEMOLITHOTROPHY (from inorganic compounds) or chemoorganotrophy (from organic compounds); and by their source for CARBON; NITROGEN; etc.; HETEROTROPHY (from organic sources) or AUTOTROPHY (from CARBON DIOXIDE). They can also be classified by whether or not they stain (based on the structure of their CELL WALLS) with CRYSTAL VIOLET dye: gram-negative or gram-positive.Bifidobacterium: A rod-shaped, gram-positive, non-acid-fast, non-spore-forming, non-motile bacterium that is a genus of the family Bifidobacteriaceae, order Bifidobacteriales, class ACTINOBACTERIA. It inhabits the intestines and feces of humans as well as the human vagina.Algorithms: A procedure consisting of a sequence of algebraic formulas and/or logical steps to calculate or determine a given task.Virulence: The degree of pathogenicity within a group or species of microorganisms or viruses as indicated by case fatality rates and/or the ability of the organism to invade the tissues of the host. The pathogenic capacity of an organism is determined by its VIRULENCE FACTORS.Neovascularization, Physiologic: The development of new BLOOD VESSELS during the restoration of BLOOD CIRCULATION during the healing process.Library Services: Services offered to the library user. They include reference and circulation.Libraries, MedicalBaltimoreCyclohexanes: Six-carbon alicyclic hydrocarbons.Vascular Endothelial Growth Factor A: The original member of the family of endothelial cell growth factors referred to as VASCULAR ENDOTHELIAL GROWTH FACTORS. Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as "tumor angiogenesis factor" and "vascular permeability factor". Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating VASODILATION via NITRIC OXIDE-dependent pathways. Alternative splicing of the mRNA for vascular endothelial growth factor A results in several isoforms of the protein being produced.Angiostatins: Circulating 38-kDa proteins that are internal peptide fragments of PLASMINOGEN. The name derives from the fact that they are potent ANGIOGENESIS INHIBITORS. Angiostatins contain four KRINGLE DOMAINS which are associated with their potent angiostatic activity.Molecular Mechanisms of Pharmacological Action: Pharmacological activities at the molecular level of DRUGS and other exogenous compounds that are used to treat DISEASES and affect normal BIOCHEMISTRY.Angiotensin Amide: The octapeptide amide of bovine angiotensin II used to increase blood pressure by vasoconstriction.Sesquiterpenes, Eudesmane: SESQUITERPENES cyclized into two adjoining cyclohexane rings but with a different configuration from the ARTEMISININS.Gymnema sylvestre: A plant species of the genus GYMNEMA that contains gymnemic acid (triterpene SAPONINS) which affects blood sugar level, and gurmarin protein. The common name of Gurmar should not be confused with Guar (CYAMOPSIS).Biological Products: Complex pharmaceutical substances, preparations, or matter derived from organisms usually obtained by biological methods or assay.Access to Information: Individual's rights to obtain and use information collected or generated by others.Health Resources: Available manpower, facilities, revenue, equipment, and supplies to produce requisite health care and services.TokyoAnimal Experimentation: The use of animals as investigational subjects.Partial Thromboplastin Time: The time required for the appearance of FIBRIN strands following the mixing of PLASMA with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of BLOOD COAGULATION. It is used as a screening test and to monitor HEPARIN therapy.PhthalazinesColonic Neoplasms: Tumors or cancer of the COLON.Mice, Nude: Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.Prothrombin Time: Clotting time of PLASMA recalcified in the presence of excess TISSUE THROMBOPLASTIN. Factors measured are FIBRINOGEN; PROTHROMBIN; FACTOR V; FACTOR VII; and FACTOR X. It is used for monitoring anticoagulant therapy with COUMARINS.Animal Care Committees: Institutional committees established to protect the welfare of animals used in research and education. The 1971 NIH Guide for the Care and Use of Laboratory Animals introduced the policy that institutions using warm-blooded animals in projects supported by NIH grants either be accredited by a recognized professional laboratory animal accrediting body or establish its own committee to evaluate animal care; the Public Health Service adopted a policy in 1979 requiring such committees; and the 1985 amendments to the Animal Welfare Act mandate review and approval of federally funded research with animals by a formally designated Institutional Animal Care and Use Committee (IACUC).Animal Welfare: The protection of animals in laboratories or other specific environments by promoting their health through better nutrition, housing, and care.Animals, LaboratorySesquiterpenesTreatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Tinea Pedis: Dermatological pruritic lesion in the feet, caused by Trichophyton rubrum, T. mentagrophytes, or Epidermophyton floccosum.Athletes: Individuals who have developed skills, physical stamina and strength or participants in SPORTS or other physical activities.Memory: Complex mental function having four distinct phases: (1) memorizing or learning, (2) retention, (3) recall, and (4) recognition. Clinically, it is usually subdivided into immediate, recent, and remote memory.Foot: The distal extremity of the leg in vertebrates, consisting of the tarsus (ANKLE); METATARSUS; phalanges; and the soft tissues surrounding these bones.Dietary Supplements: Products in capsule, tablet or liquid form that provide dietary ingredients, and that are intended to be taken by mouth to increase the intake of nutrients. Dietary supplements can include macronutrients, such as proteins, carbohydrates, and fats; and/or MICRONUTRIENTS, such as VITAMINS; MINERALS; and PHYTOCHEMICALS.Memory, Long-Term: Remembrance of information from 3 or more years previously.Gliosarcoma: Rare mixed tumors of the brain and rarely the spinal cord which contain malignant neuroectodermal (glial) and mesenchymal components, including spindle-shaped fibrosarcoma cells. These tumors are highly aggressive and present primarily in adults as rapidly expanding mass lesions. They may arise in tissue that has been previously irradiated. (From Br J Neurosurg 1995 Apr;9(2):171-8)Blood Volume: Volume of circulating BLOOD. It is the sum of the PLASMA VOLUME and ERYTHROCYTE VOLUME.Antineoplastic Agents: Substances that inhibit or prevent the proliferation of NEOPLASMS.IndazolesCell Line, Tumor: A cell line derived from cultured tumor cells.Protein Kinase Inhibitors: Agents that inhibit PROTEIN KINASES.Cyclophosphamide: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.Photoacoustic Techniques: Investigative and diagnostic methods and procedures based on the photoacoustic effect, which is the generation of SOUND WAVES from the absorption of ELECTROMAGNETIC RADIATION.Microscopy, Acoustic: A scientific tool based on ULTRASONOGRAPHY and used not only for the observation of microstructure in metalwork but also in living tissue. In biomedical application, the acoustic propagation speed in normal and abnormal tissues can be quantified to distinguish their tissue elasticity and other properties.Chick Embryo: The developmental entity of a fertilized chicken egg (ZYGOTE). The developmental process begins about 24 h before the egg is laid at the BLASTODISC, a small whitish spot on the surface of the EGG YOLK. After 21 days of incubation, the embryo is fully developed before hatching.Microscopy: The use of instrumentation and techniques for visualizing material and details that cannot be seen by the unaided eye. It is usually done by enlarging images, transmitted by light or electron beams, with optical or magnetic lenses that magnify the entire image field. With scanning microscopy, images are generated by collecting output from the specimen in a point-by-point fashion, on a magnified scale, as it is scanned by a narrow beam of light or electrons, a laser, a conductive probe, or a topographical probe.Optical Processes: Behavior of LIGHT and its interactions with itself and materials.Chorioallantoic Membrane: A highly vascularized extra-embryonic membrane, formed by the fusion of the CHORION and the ALLANTOIS. It is mostly found in BIRDS and REPTILES. It serves as a model for studying tumor or cell biology, such as angiogenesis and TISSUE TRANSPLANTATION.Ear: The hearing and equilibrium system of the body. It consists of three parts: the EXTERNAL EAR, the MIDDLE EAR, and the INNER EAR. Sound waves are transmitted through this organ where vibration is transduced to nerve signals that pass through the ACOUSTIC NERVE to the CENTRAL NERVOUS SYSTEM. The inner ear also contains the vestibular organ that maintains equilibrium by transducing signals to the VESTIBULAR NERVE.Microvessels: The finer blood vessels of the vasculature that are generally less than 100 microns in internal diameter.COUP Transcription Factor II: A COUP transcription factor that negatively regulates GENETIC TRANSCRIPTION and competes with other hormone receptors for the common response element AGGTCA. It can also stimulate transcription of genes involved in the metabolism of GLUCOSE and CHOLESTEROL.Psoralens: Linear furanocoumarins which are found in many PLANTS, especially UMBELLIFERAE and RUTACEAE, as well as PSORALEA from which they were originally discovered. They can intercalate DNA and, in an UV-initiated reaction of the furan portion, alkylate PYRIMIDINES, resulting in PHOTOSENSITIVITY DISORDERS.Endothelial Cells: Highly specialized EPITHELIAL CELLS that line the HEART; BLOOD VESSELS; and lymph vessels, forming the ENDOTHELIUM. They are polygonal in shape and joined together by TIGHT JUNCTIONS. The tight junctions allow for variable permeability to specific macromolecules that are transported across the endothelial layer.Coumarins: Synthetic or naturally occurring substances related to coumarin, the delta-lactone of coumarinic acid.Benztropine: A centrally active muscarinic antagonist that has been used in the symptomatic treatment of PARKINSON DISEASE. Benztropine also inhibits the uptake of dopamine.Cells, Cultured: Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.

Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effect. (1/4006)

Angiogenesis is required for the growth and progression of malignancies. Recent studies have demonstrated that genetic alterations may accompany acquisition of the angiogenic phenotype. The tumor suppressor gene p53 is most frequently mutated in human cancers and is also known to be a transcriptional regulator of a variety of genes. Here, we investigated the antiangiogenic effect of the wild-type p53 (wt-p53) gene transfer on a human non-small cell lung cancer cell line. Mutant p53-expressing H226Br non-small cell lung cancer cells were transduced with the wt-p53 gene using a recombinant adenoviral vector (Ad5CMVp53) and applied to semiquantitative reverse transcription-PCRs for the detection of altered mRNA expression of angiogenic and/or antiangiogenic factors. In vivo neovascularization assay of Ad5CMVp53-infected cells was then performed using a membrane-diffusion chamber system s.c. transplanted in nu/nu mice. We also evaluated the effect of Ad5CMVp53-infected H226Br cells on nontransduced tumor cells in vivo by s.c. inoculating mixture of cells into nu/nu mice. Ad5CMVp53 infection markedly inhibited the expression of an angiogenic factor, vascular endothelial growth factor, and increased the expression of a novel antiangiogenic factor, brain-specific angiogenesis inhibitor 1, resulting in reduced neovascularization in vivo. Mixing experiments showed that tumor cells transduced with the wt-p53 gene inhibited the in vivo tumor growth of adjacent nontransduced cells. Our data suggest that a recombinant adenovirus expressing the wt-p53 gene is antiangiogenic, which may explain, in part, the mechanism of the bystander effect induced by the wt-p53 gene transfer on adjacent tumor cells.  (+info)

Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth. (2/4006)

Several angiogenesis inhibitors are fragments of larger proteins that are themselves not active as angiogenesis inhibitors. Vasostatin, the N-terminal domain of calreticulin inclusive of amino acids 1-180, is an angiogenesis inhibitor that exerts antitumor effects in vivo. In the present study, we examined whether the full-length calreticulin molecule shares the antiangiogenic and antitumor activities of vasostatin. Similar to vasostatin, calreticulin selectively inhibited endothelial cell proliferation in vitro, but not cells of other lineages, and suppressed angiogenesis in vivo. When inoculated into athymic mice, calreticulin inhibited Burkitt tumor growth comparably with vasostatin. Calreticulin lacking the N-terminal 1-120 amino acids inhibited endothelial cell proliferation in vitro and Burkitt tumor growth in vivo comparably with vasostatin. An internal calreticulin fragment encompassing amino acids 120-180 also inhibited endothelial cell proliferation in vitro and angiogenesis in vivo comparably with calreticulin and vasostatin. These results suggest that the antiangiogenic activities of vasostatin reside in a domain that is accessible from the full-length calreticulin molecule and localize to calreticulin N-terminal amino acids 120-180. Thus, calreticulin and calreticulin fragments are inhibitors of angiogenesis that directly target endothelial cells, inhibit angiogenesis, and suppress tumor growth. This information may be critical in designing targeted inhibitors of pathological angiogenesis that underlies cancer and other diseases.  (+info)

Inhibition of angiogenesis and intrahepatic growth of colon cancer by TAC-101. (3/4006)

We demonstrated in this study that inhibition of intra-hepatic growth of colon cancer by TAC-101 is mediated by inhibition of angiogenesis. In vitro experiments showed that TAC-101 inhibited the proliferation of murine hepatic sinusoidal endothelial (HSE) cells induced by coculture with murine colon 26-L5 (L5) cells. HSE cell proliferation was also enhanced by conditioned medium of L5 cells (CM-L5), and this enhancement of proliferation was abrogated by anti-vascular endothelial growth factor antibody. CM-L5 also induced in vitro tube formation of HSE cells on Matri-gel, and this activity of CM-L5 was abrogated by TAC-101 in a concentration-dependent manner. On the other hand, p.o. administration of TAC-101 inhibited tumor-induced angiogenesis in vivo and decreased the weights of L5 tumors in the mouse liver. Reverse transcriptase-PCR analysis using in vivo tumor tissue suggested that repression of vascular endothelial growth factor expression by TAC-101 was associated with the antiangiogenic activity. TAC-101 alone and 5-fluorouracil (5-FU)/D,L-leucovorin (LV) significantly inhibited the intrahepatic growth of L5 tumors (P = 0.002 and 0.001, respectively), whereas 5-FU alone did not (P = 0.088). When TAC-101 was administered with 5-FU/LV, marked enhancement of antitumor activity was observed (95% inhibition; P<0.001). This enhanced antitumor effect was also observed in experiments using Co-3 human colon adenocarcinoma. Concurrent treatment with TAC-101 and 5-FU/LV and sequential treatment with 5-FU/LV followed by TAC-101 resulted in significant augmentation of antitumor activity against Co-3 (overall P = 0.007 and 0.015, respectively). These findings indicate that TAC-101 inhibits tumor angiogenesis and suggest that it may be effective against hepatic metastasis of colon cancer.  (+info)

A pharmacokinetically guided Phase II study of carboxyamido-triazole in androgen-independent prostate cancer. (4/4006)

We conducted a Phase II clinical trial of the antiproliferative, antimetastatic, and antiangiogenic agent carboxyamido-triazole (CAI), using pharmacokinetic assessment to guide drug dosing. Fifteen patients who had stage D2 androgen-independent prostate cancer with soft tissue metastases were enrolled. Because CAI previously had been shown to decrease prostate-specific antigen secretion in vitro, this marker was not used to assess disease status. The dose of CAI used in this study was calculated so that plasma steady-state maximum concentrations between 2.0 and 5.0 microg/ml would be maintained. Following the initial dosage adjustment, 93% (14 of 15) of patients were within the predicted range. Fourteen of 15 patients were evaluable for response. All of the 14 evaluable patients demonstrated progressive disease at approximately 2 months. Twelve patients progressed by computed tomography and or bone scan at 2 months, whereas two patients demonstrated clinical progression at 1.5 and 2 months. One patient was removed from study at 6 weeks due to grade II peripheral neuropathy lasting >1 month. Although no clinical responses were noted, a 27.7% decrease in serum vascular endothelial growth factor concentration was observed. CAI does not possess clinical activity in patients with androgen-independent prostate cancer and soft tissue metastases. Pharmacokinetically guided dosing, although found to be feasible using a Bayesian approach, was not found to be of practical benefit. Although plasma CAI concentrations were maintained within the designated range, grade III toxicity requiring drug discontinuation was still observed.  (+info)

Angiogenesis inhibitor endostatin is a distinct component of elastic fibers in vessel walls. (5/4006)

Theendothelial cell inhibitor endostatin (22 kDa) is part of the carboxyl-terminal globular domain of collagen XVIII and shows a widespread tissue distribution. Immunohistology of adult mouse tissues demonstrated a preferred localization in many vessel walls and some other basement membrane zones. A strong immunogold staining was observed across elastic fibers in the multiple elastic membranes of aorta and other large arteries. Staining was less strong along sparse elastic fibers of veins and almost none was observed in the walls of arterioles and capillaries. Strong evidence was also obtained for some intracellular and basement membrane associations. Immunogold double staining of elastic fibers showed a close colocalization of endostatin with fibulin-2, fibulin-1, and nidogen-2, but not with perlecan. Reasonable amounts of endostatin could be extracted from aorta and skin by EDTA, followed by detergents, with aorta being the richest source of the inhibitor identified so far. Solubilizations with collagenase and elastase were approximately fivefold less efficient. Immunoblots of aortic extracts detected major endostatin components of 22-25 kDa whereas skin extracts also contained some larger components. Solid-phase assays demonstrated distinct binding of recombinant mouse endostatin to the fibulins and nidogen-2, consistent with their tissue colocalization. Together, the data indicate several different ways for endostatin to be associated with the extracellular matrix, and its release may determine biological activation. This also defines a novel function for some elastic tissues.  (+info)

Antiangiogenic activity of prostate-specific antigen. (6/4006)

BACKGROUND: Measurement of serum levels of prostate-specific antigen (PSA) is widely used as a screening tool for prostate cancer. However, PSA is not prostate specific, having been detected in breast, lung, and uterine cancers. In one study, patients whose breast tumors had higher levels of PSA had a better prognosis than patients whose tumors had lower PSA levels. To test the hypothesis that PSA may have antiangiogenic properties, we evaluated the effects of PSA on endothelial cell proliferation, migration, and invasion, which are key steps in angiogenesis, the process by which tumors develop a blood supply. METHODS: To assess the antiproliferative effects of PSA, we treated bovine endothelial cells and human endothelial cell lines (HUVEC and HMVEC-d) with purified human PSA (0.1-10 microM) and then stimulated them with 10 ng/mL fibroblast growth factor-2 (FGF-2). Effects on FGF-2- or vascular endothelial growth factor (VEGF)-stimulated endothelial cell migration, invasion, and tube formation were measured by use of one cell line only (HUVEC). PSA was administered to mice at 9 microM for 11 consecutive days after intravenous inoculation of B16BL6 melanoma cells to assess its ability to inhibit the formation of lung colonies (i.e., metastatic tumors). RESULTS: PSA inhibited endothelial cell proliferation, migration, and invasion at IC(50) (i. e., the concentration at which inhibition was 50%) values ranging from 0.3-5 microM. In addition, PSA inhibited endothelial cell responses to both angiogenic stimulators tested, FGF-2 and VEGF. In a mouse model of metastatic disease, daily PSA treatment resulted in a 40% reduction in the mean number of lung tumor nodules compared with phosphate-buffered saline treatment (two-sided P =.003). CONCLUSION: To our knowledge, this is the first report that PSA may function in tumors as an endogenous antiangiogenic protein. This function may explain, in part, the naturally slow progression of prostate cancer. Our findings call into question various strategies to inhibit the expression of PSA in the treatment of prostate cancer.  (+info)

Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action. (7/4006)

Recent evolutionary studies reveal that microorganisms including yeasts and fungi are more closely related to mammals than was previously appreciated. Possibly as a consequence, many natural-product toxins that have antimicrobial activity are also toxic to mammalian cells. While this makes it difficult to discover antifungal agents without toxic side effects, it also has enabled detailed studies of drug action in simple genetic model systems. We review here studies on the antifungal actions of antineoplasmic agents. Topics covered include the mechanisms of action of inhibitors of topoisomerases I and II; the immunosuppressants rapamycin, cyclosporin A, and FK506; the phosphatidylinositol 3-kinase inhibitor wortmannin; the angiogenesis inhibitors fumagillin and ovalicin; the HSP90 inhibitor geldanamycin; and agents that inhibit sphingolipid metabolism. In general, these natural products inhibit target proteins conserved from microorganisms to humans. These studies highlight the potential of microorganisms as screening tools to elucidate the mechanisms of action of novel pharmacological agents with unique effects against specific mammalian cell types, including neoplastic cells. In addition, this analysis suggests that antineoplastic agents and derivatives might find novel indications in the treatment of fungal infections, for which few agents are presently available, toxicity remains a serious concern, and drug resistance is emerging.  (+info)

Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. (8/4006)

The effects of the angiogenic inhibitors endostatin, angiostatin, and TNP-470 on tumor growth dynamics are experimentally and theoretically investigated. On the basis of the data, we pose a quantitative theory for tumor growth under angiogenic stimulator/inhibitor control that is both explanatory and clinically implementable. Our analysis offers a ranking of the relative effectiveness of these inhibitors. Additionally, it reveals the existence of an ultimate limitation to tumor size under angiogenic control, where opposing angiogenic stimuli come into dynamic balance, which can be modulated by antiangiogenic therapy. The competitive influences of angiogenically driven growth and inhibition underlying this framework may have ramifications for tissue size regulation in general.  (+info)

*Angiogenesis inhibitor

See [1] and [2] Angiogenesis Inhibitors for Cancer - from The Angiogenesis Foundation, 23 June 2009 Angiogenesis Inhibitors for ... An angiogenesis inhibitor is a substance that inhibits the growth of new blood vessels (angiogenesis). Some angiogenesis ... 23 June 2009 Angiogenesis Inhibitors in the Treatment of Cancer - from the National Cancer Institute Angiogenesis Inhibitors at ... and are thus destroyed by angiogenesis inhibitors. Angiogenesis inhibitors are also used as treatment for the wet form of ...

*Cartilage-derived angiogenesis inhibitor

A cartilage-derived angiogenesis inhibitor is an angiogenesis inhibitor produced from cartilage. Examples include the peptide ... a cartilage-derived angiogenesis inhibitor: in vitro and in vivo effects on human endothelial cells and on pancreatic cancer". ... March 2004). "Suppression of T cell responses by chondromodulin I, a cartilage-derived angiogenesis inhibitory factor: ...

*Brain-specific angiogenesis inhibitor

... 1 Brain-specific angiogenesis inhibitor 2 Brain-specific angiogenesis inhibitor 3 ... Brain-specific angiogenesis inhibitors are G-protein coupled receptors belonging to the class B secretin subfamily. Members ... novel genes homologous to brain-specific angiogenesis inhibitor 1 (BAI1)". Cytogenet. Cell Genet. 79 (1-2): 103-8. doi:10.1159/ ...

*Brain-specific angiogenesis inhibitor 2

... is a protein that in humans is encoded by the BAI2 gene. It is a member of the adhesion ... BAI1, a p53-target gene, encodes brain-specific angiogenesis inhibitor, a seven-span transmembrane protein and is thought to be ... 2002). "Expression of brain-specific angiogenesis inhibitor 2 (BAI2) in normal and ischemic brain: involvement of BAI2 in the ... "Entrez Gene: BAI2 brain-specific angiogenesis inhibitor 2". Stacey, edited by Simon Yona, Martin (2010). Adhesion-GPCRs : ...

*Brain-specific angiogenesis inhibitor 3

... is a protein that in humans is encoded by the BAI3 gene. BAI1, a p53-target gene, ... "Entrez Gene: BAI3 brain-specific angiogenesis inhibitor 3". Marc F. Bolliger, David C. Martinelli, and Thomas C. Südhof. The ... encodes brain-specific angiogenesis inhibitor, a seven-span transmembrane protein and is thought to be a member of the secretin ... novel genes homologous to brain-specific angiogenesis inhibitor 1 (BAI1)". Cytogenet Cell Genet. 79 (1-2): 103-8. doi:10.1159/ ...

*Brain-specific angiogenesis inhibitor 1

... an inhibitor of angiogenesis and a growth suppressor of glioblastomas. Brain-specific angiogenesis inhibitor 1 has been shown ... Brain-specific angiogenesis inhibitor 1 is a protein that in humans is encoded by the BAI1 gene. It is a member of the adhesion ... "Overexpression of the p53-inducible brain-specific angiogenesis inhibitor 1 suppresses efficiently tumour angiogenesis". ... Angiogenesis is controlled by a local balance between stimulators and inhibitors of new vessel growth and is suppressed under ...

*Development of analogs of thalidomide

Inhibition of TNF-α is not the mechanism of thalidomide's inhibition of angiogenesis since numerous other TNF-α inhibitors do ... D'Amato RJ, Loughnan MS, Flynn E, Folkman J (April 1994). "Thalidomide is an inhibitor of angiogenesis". Proc. Natl. Acad. Sci ... Additionally, these analogs are more potent inhibitors of angiogenesis than thalidomide. As well, the amino-thalidomide and ... "Angiogenesis inhibitors derived from thalidomide". Bioorganic & Medicinal Chemistry Letters. 15 (24): 5509-5513. doi:10.1016/j. ...

*Thrombospondin

Sorbera LA, Bayes M (2005). "ABT-510: oncolytic angiogenesis inhibitor". Drugs of the future. Prous Science. 30 (11): 1081-6. ... April 2005). "Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization ... Since tumors overexpressing TSP-1 typically grow slower, exhibit less angiogenesis, and have fewer metastases, TSP1 is an ... functions for TSP-1 have been found in multiple biological processes including angiogenesis, apoptosis, activation of TGF-beta ...

*Angiozyme

It belongs to the families of drugs called VEGF receptor and angiogenesis inhibitors. Preliminary tests have demonstrated that ... Weng, D. E.; Usman, N. (March 2001). "Angiozyme: a novel angiogenesis inhibitor". Current Oncology Reports. 3 (2): 141-146. ... Angiogenesis has no significant side effects. the Also called RPI.4610 Angiozyme entry in the public domain NCI Dictionary of ...

*Matrix metalloproteinase inhibitor

There are also cartilage-derived angiogenesis inhibitors. Exogenous matrix metalloproteinase inhibitors were developed as ... Drug discovery and development of MMP inhibitors Coussens, L. M. (2002). "Matrix Metalloproteinase Inhibitors and Cancer-- ... A matrix metalloproteinase inhibitor (MMPI) inhibits matrix metalloproteinases. As they inhibit cell migration they have ... Noel Vinay Thomas; Se Kwon Kim (2010). "Metalloproteinase Inhibitors Stts and Scope from Marine Organisms". Biochemistry ...

*Tumor-associated endothelial cell

Various angiogenesis inhibitors have been developed to interfere with different steps in the process. Bevacizumab (Avastin) is ... Sorafenib and sutinib are additional angiogenesis inhibitors that bind and block receptors on endothelial cells that have ... Cook, Kristina M.; Figg, William D. (2010-07-01). "Angiogenesis inhibitors: current strategies and future prospects". CA: a ... Shih, Ted; Lindley, Celeste (2006-11-01). "Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies". ...

*Diabetic retinopathy

Ryeom, Sandra; Folkman, Judah (2009). "Role of Endogenous Angiogenesis Inhibitors in Down Syndrome". Journal of Craniofacial ... Since 2008 there have been other therapies (e.g. kinase inhibitors and anti-VEGF) drugs available. Laser photocoagulation can ...

*Endostatin

Among anti-angiogenesis inhibitors, endostatin has a wide range of anti-cancer spectrum targets, increasing its significance ... Endogenous inhibitors of angiogenesis are present in both normal tissue and cancerous tissue. Overall, endostatin down ... Endostatin is a broad-spectrum angiogenesis inhibitor and may interfere with the pro-angiogenic action of growth factors such ... Hohenester, E.; Sasaki, T.; Olsen, B.R.; Timpl, R. (1998). "Crystal structure of the angiogenesis inhibitor endostatin at 1.5 A ...

*MY-5445

... is a relatively specific phosphodiesterase 5 inhibitor. Vatalanib - a structurally related angiogenesis inhibitor ... a Specific Inhibitor of Cyclic GMP Phosphodiesterase, on Human Platelet Aggregation". The Journal of Pharmacology and ...

*Secretin receptor family

Brain-specific angiogenesis inhibitor InterPro: IPR008077 BAI1; BAI2; BAI3 CD97 antigen InterPro: IPR003056 CD97 EMR hormone ... calcium-independent receptors for latrotoxin and brain-specific angiogenesis inhibitor receptors amongst others. ...

*TNNI2

Li Q, Shen PY, Wu G, Chen XZ (Jan 2003). "Polycystin-2 interacts with troponin I, an angiogenesis inhibitor". Biochemistry. 42 ... Perry SV (Jan 1999). "Troponin I: inhibitor or facilitator". Molecular and Cellular Biochemistry. 190 (1-2): 9-32. doi:10.1023/ ... "Troponin I is present in human cartilage and inhibits angiogenesis". Proceedings of the National Academy of Sciences of the ... "Troponin I is present in human cartilage and inhibits angiogenesis". Proceedings of the National Academy of Sciences of the ...

*Causes of cancer pain

... angiogenesis inhibitors like bevacizumab, known to sometimes cause bone pain; and surgery, which may produce post-operative ... Aromatase inhibitors can cause diffuse muscle and joint pain and stiffness, and may increase the likelihood of osteoporosis and ... the proteasome inhibitors such as bortezomib, and the platinum-based drugs cisplatin, oxaliplatin and carboplatin. Whether CIPN ...

*Endometriosis

... endogenous angiogenesis inhibitors, fumagillin analogues, statins, cyclo-oxygenase-2 inhibitors, phytochemical compounds, ... Angiogenesis inhibitors lack clinical evidence of efficacy in endometriosis therapy. Under experimental in vitro and in vivo ... Examples of aromatase inhibitors include anastrozole and letrozole. Evidence for aromatase inhibitors is limited due to the ... Aromatase inhibitors are medications that block the formation of estrogen and have become of interest for researchers who are ...

*Cancer pain

... angiogenesis inhibitors like bevacizumab, known to sometimes cause bone pain; surgery, which may produce post-operative pain, ... non-steroidal anti-inflammatory drugs or COX-2 inhibitors. Then, if complete pain relief is not achieved or disease progression ...

*Polycystin 2

... an angiogenesis inhibitor". Biochemistry. United States. 42 (2): 450-7. doi:10.1021/bi0267792. ISSN 0006-2960. PMID 12525172. ...

*C-Met

Poster Matsumoto K, Nakamura T (April 2003). "NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics". ... Moreover, MET inhibitors, such as Crizotinib or PF-04254644, have been tested by short-term treatments in cellular and ... MP470 (SuperGen) is a novel inhibitor of c-KIT, MET, PDGFR, Flt3, and AXL. Phase I clinical trial of MP470 had been announced ... The major limitation of HGF inhibitors is that they block only HGF-dependent MET activation. NK4 competes with HGF as it binds ...

*Fumagillin

... an anti-infective as a parent molecule for novel angiogenesis inhibitors". Expert Rev Anti Infect Ther. 5 (4): 573-9. doi: ... are investigated as an angiogenesis inhibitor in the treatment of cancer. The company Zafgen conducted clinical trials using ... Fumagillin is also investigated as an inhibitor of malaria parasite growth. Fumagillin has been used in the treatment of ... "Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth". Nature. 348 (6301): 555-557. Bibcode: ...

*Yihai Cao

Cao participated in the discovery of angiostatin, an endogenous angiogenesis inhibitor, in Judah Folkman ́s Laboratory. He ... Cao´s laboratory discovered catechins in green tea as oral angiogenesis inhibitors. They also discovered several ... is an angiogenesis inhibitor that suppresses the growth of Lewis lung carcinoma in mice". The Journal of Experimental Medicine ... a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma". Cell. 79 (2): 315-328. ...

*METAP2

Griffith EC, Su Z, Niwayama S, Ramsay CA, Chang YH, Liu JO (December 1998). "Molecular recognition of angiogenesis inhibitors ... is the common target for angiogenesis inhibitors AGM-1470 and ovalicin". Chem. Biol. 4 (6): 461-71. doi:10.1016/S1074-5521(97) ... thereby inhibiting angiogenesis. The way in which MetAP2 regulates angiogenesis has yet to be established, however, such that ... MetAP2 inhibitors work by re-establishing balance to the ways the body metabolizes fat, leading to substantial loss of body ...

*BAIAP3

BAI1 is a p53-target gene that encodes a brain-specific angiogenesis inhibitor. The protein is a seven-span transmembrane ... BAIAP3 interacts with the cytoplasmic region of brain-specific angiogenesis inhibitor 1. BAIAP3 also contains two C2 domains, ... BAIAP3 has been shown to interact with Brain-specific angiogenesis inhibitor 1. GRCh38: Ensembl release 89: ENSG00000007516 - ...

*Prostaglandin-endoperoxide synthase 2

Non-substrate FAs can potentiate or attenuate PTGS (COX) inhibitors depending on the fatty acid and whether the inhibitor binds ... The overexpression of PTGS2 (COX-2) along with increased angiogenesis and SLC2A1 (GLUT-1) expression is significantly ... PGHSs are targets for NSAIDs and PTGS2 (COX-2) specific inhibitors called coxibs. PGHS-2 is a sequence homodimer. Each monomer ... Substrate and non-substrate fatty acid (FAs) and some PTGS (COX) inhibitors (e.g. naproxen) preferentially bind to the PTGS ( ...
Summary Ziv-aflibercept (Zaltrap, Regeneron Pharmaceuticals and sanofi-aventis) is a novel recombinant fusion protein that targets the angiogenesis signaling pathway of tumor cells by blocking vascular endothelial growth factor (VEGF) receptors that play a key role in tumor growth and metastasis; it is a more potent VEGF blocker than bevacizumab. Ziv-aflibercept is approved by the Food and Drug Administration for use in combination with fluorouracil, irinotecan, and leucovorin (the FOLFIRI regimen) for second-line treatment of patients with mCRC who have disease progression during first-line oxaliplatin-based chemotherapy. A Phase III trial demonstrated that relative to FOLFIRI therapy alone, the use of ziv-aflibercept was associated with significantly improved patient response, overall survival, and progression-free survival in patients with good performance status at baseline, including some who had received prior bevacizumab therapy. The most common grade 3 or 4 adverse effects associated ...
Angiogenesis is defined as the formation of new blood vessels from pre-existing vasculature. Angiogenesis is relevant not just to disease tumors and to non-neoplastic diseases most notably macular degeneration, psoriasis, endometriosis, {and,as well as arthritis. The development {and,because well as metastasis of tumors tend to be really critically dependent upon angiogenesis. Therefore, the inhibition of angiogenesis grew to become {an,a particular,a few sort of,some of important therapeutic approach for cancer. Although the existing anti-angiogenesis options have been stated to have less toxicity than conventional chemo {or, alternatively perhaps radiotherapy, they are frequently connected with clinical side impacts, {and,since well also limited tumor regression. Therefore, there has become {an,a particular,a bunch of type of,a few of increased focus towards development of novel angiogenesis inhibitors {and,also as book approaches to improve the anti-angiogenic options .. Human apolipoprotein ...
Sigma-Aldrich offers abstracts and full-text articles by [Jae Hyeon Kim, Jin-Kyu Kim, Eun-Kyung Ahn, Hye-Jin Ko, Young-Rak Cho, Choong Hyun Lee, Yong Kee Kim, Gyu-Un Bae, Joa Sub Oh, Dong-Wan Seo].
The Antiangiogenic Compound Aeroplysinin-1 Induces Apoptosis in Endothelial Cells by Activating the Mitochondrial Pathway. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
To further investigate the role of CD11b+Gr1+ cells in refractoriness to anti-VEGF, we also treated the same tumors with mFlt(1-3)-IgG, a high affinity chimeric-soluble VEGFR-1 variant that not only neutralizes VEGF-A but also PlGF and VEGF-B ( 23). We saw no difference between anti-VEGF or mFlt(1-3)-IgG-treated groups in the efficiency of tumor formation or in the accumulation of CD11b+Gr1+ cells, suggesting that VEGFR-1 selective ligands do not compensate for the lack of VEGF-A, at least under these experimental circumstances. In apparent conflict with these conclusions, Fisher and colleagues ( 24) recently reported that targeting PlGF alone with neutralizing antibodies elicits significant antitumor effects in some anti-VEGF refractory models. Elucidating the reasons for such discrepancy will require further investigation. In addition, to address whether a lack of response to anti-VEGF might reflect a general refractoriness to other antitumor agents, we treated tumor-bearing mice with several ...
TL-118 is an anti-angiogenic drug combination designed for the treatment of cancer. The investigational product Tl-118 comprises of four well-known active components. The therapy is administrated at a unique dosing regimen that was found to be effective and advantageous in terms of safety. The product is formulated as an oral suspension, conveniently administrated by the patients at home and not requiring medical staff assistance. This Phase II clinical trial aims to evaluate the efficacy, safety and tolerability of TL-118 in Gemcitabine treated Pancreatic Cancer ...
University of Pittsburgh scientists have shown that triggering an anti-tumor immune response significantly potentiates the effects of the anti-angiogenic drug endostatin in animal models, leading to permanent and complete regression...
The treatment of the most common cancers (colon, breast, lung, liver and kidney) has recently added a new therapeutic class known as the anti-angiogenic. It was born from a better understanding of tumor growth requires the development of neo-vessels. These new vessels are of major importance for the viability of the tumor but also the birth of metastases. This neo-angiogenesis is complex and results from an imbalance between pro-angiogenic factors and anti-angiogenic factors. Growth factor VEGF and its receptors (VEGFR-1, VEGFR-2 and VEGFR-3) are a way of survival of endothelial cells required for tumor neoangiogenesis. The anti-angiogenic drugs currently available on the market are bevacizumab (Avastin ®), sunitinib (Sutent ®) and sorafenib (Nexavar ®). The mechanism of anti-angiogenic action of these three main drugs are pharmacological inhibition of the VEGF pathway.. These new anti-angiogenic therapies, however, have significant adverse effects are common and some other more serious but ...
TY - JOUR. T1 - Vascular Mimicry. T2 - A Novel Neovascularization Mechanism Driving Anti-Angiogenic Therapy (AAT) Resistance in Glioblastoma. AU - Angara, Kartik. AU - Borin, Thaiz Ferraz. AU - Arbab, Ali Syed. PY - 2017/8/1. Y1 - 2017/8/1. N2 - Glioblastoma (GBM) is a hypervascular neoplasia of the central nervous system with an extremely high rate of mortality. Owing to its hypervascularity, anti-angiogenic therapies (AAT) have been used as an adjuvant to the traditional surgical resection, chemotherapy, and radiation. The benefits of AAT have been transient and the tumors were shown to relapse faster and demonstrated particularly high rates of AAT therapy resistance. Alternative neovascularization mechanisms were shown to be at work in these resilient tumors to counter the AAT therapy insult. Vascular Mimicry (VM) is the uncanny ability of tumor cells to acquire endothelial-like properties and lay down vascular patterned networks reminiscent of host endothelial blood vessels. The VM channels ...
Beverly Teicher and a panel of distinguished investigators survey the state-of-the-art of antiangiogenesis research from the lab bench to clinical trials. Timely and authoritative, the contributors summarize our current understanding of tumor growth and its dependence on vascular development, as well as the present status of antiangiogenic agents in preclinical and clinical development. In addition, the book also examines what is known about the mechanisms by which these therapeutic agents interfere with tumor vasculature and grapples with the problem of establishing criteria by which to assess their clinical efficacy. Antiangiogenic Agents in Cancer Therapy offers a unique cutting-edge compendium of antiangiogenic research, taking stock of what has been accomplished , where the experimental therapeutics of antiangiogenic agents is going, and the continuing evolution of their role in cancer treatment and novel drug development ...
Poster (2011, January 31). DNA methylation and histone deacetylation are two key epigenetic modifications that play central role in regulation of gene expression. Several studies have shown that histone deacetylases (HDAC) and DNA ... [more ▼]. DNA methylation and histone deacetylation are two key epigenetic modifications that play central role in regulation of gene expression. Several studies have shown that histone deacetylases (HDAC) and DNA methyltransferases (DNMT) inhibitors are potent anti-angiogenic compounds. Though combination of HDAC and DNMT inhibitors are now being examined in clinical trials of hematological malignancies, little work has been done to understand the effect of this combination on physiological and tumoral angiogenesis. We have designed and tested a family of twin drugs with intrinsic HDAC and DNMT inhibitory activities in relevant models of angiogenesis in vitro (Human Umbilical Vein Endothelial Cells - HUVEC and aortic ring) and in vivo (chick chorioallantoic ...
Poster (2011, January 31). DNA methylation and histone deacetylation are two key epigenetic modifications that play central role in regulation of gene expression. Several studies have shown that histone deacetylases (HDAC) and DNA ... [more ▼]. DNA methylation and histone deacetylation are two key epigenetic modifications that play central role in regulation of gene expression. Several studies have shown that histone deacetylases (HDAC) and DNA methyltransferases (DNMT) inhibitors are potent anti-angiogenic compounds. Though combination of HDAC and DNMT inhibitors are now being examined in clinical trials of hematological malignancies, little work has been done to understand the effect of this combination on physiological and tumoral angiogenesis. We have designed and tested a family of twin drugs with intrinsic HDAC and DNMT inhibitory activities in relevant models of angiogenesis in vitro (Human Umbilical Vein Endothelial Cells - HUVEC and aortic ring) and in vivo (chick chorioallantoic ...
In chapter 1, we sought a proof of principle to confirm that the blocking of angiogenesis does indeed improve cartilage formation when using genetically-modified nasal chondrocytes (NCs) or antiangiogenic peptides associated with NCs. For this purpose, NCs were genetically-modified to express mouse soluble VEGF receptor-2 (sFlk-1) or were associated with an antiangiogenic peptide in order to have their chondrogenic capacity assessed in vitro and in vivo. Improved cartilage regeneration could be observed after in vivo implantation of NCs in an ectopic nude mouse model. Whereas the anti-angiogenic approaches did not improve chondrogenesis in vitro, frank chondrogenesis occured in vivo only in the constructs generated by NCs expressing sFlk-1 or treated with the peptide. Blood vessel ingrowth was significantly hampered in the anti-angiogenic experimental groups when compared with naïve NCs, which correlated with chondrogenis improvement. Strikingly, the anti-angiogenic effect was even more evident ...
83 Angiogenesis is essential for tumor growth, invasion and metastatic spread. The fibrinolytic system has been shown to play a role in this process and on the prognosis for survival of patient with many cancers such as gliomas. In our previous study, Neovastat, a standardized extract of marine cartilage with multiple antiangiogenic properties, has been shown to stimulate t-PA activity in an colorimetric in vitro assay and in treated tumor homogenates, but more precision were needed to make conclusion on its relevance on the inhibition of angiogenesis and tumors growth. We used SELDI-TOF to study the pharmacokinetic of the compound in mice and human plasma. We identified many proteins present in the coumpound that also appear in the plasma of both species 2-4 h after per os administration. In glioma bearing mice, specific proteomic patterns were detected in plasma indicative of the in vivo antiangiogenic efficacy of Neovastat. Long oligonucleotide microarray also showed that Neovastat can induce ...
Uncontrolled neovascularization occurs in several angiogenesis-dependent diseases, including cancer. Neovascularization is tightly controlled by the balance between angiogenic growth factors and antiangiogenic agents. The various natural angiogenesis inhibitors identified so far affect neovascularization by different mechanisms of action. Thrombospondin-1 (TSP-1) is a matricellular modular glycoprotein that acts as a powerful endogenous inhibitor of angiogenesis. It acts both indirectly, by sequestering angiogenic growth factors and effectors in the extracellular environment, and directly, by inducing an antiangiogenic program in endothelial cells following engagement of specific receptors including CD36, CD47, integrins and proteoglycans (all involved in angiogenesis ). In view of its central, multifaceted role in angiogenesis, TSP-1 has served as a source of antiangiogenic tools, including TSP-1 fragments, synthetic peptides and peptidomimetics, gene therapy strategies, and agents that up-regulate TSP
Health, ...The beneficial effects of anti-angiogenesis drugs in the treatment of ... Our findings suggest that antiangiogenesis therapy can increase patie...Cediranib inhibits the potent angiogenesis factor VEGF which is known... We frequently see beneficial effects from drugs in patients without f...,Angiogenesis,inhibitor,improves,brain,tumor,survival,by,reducing,edema,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
The results of preclinical studies are often contradictory with regard to the efficacy of anti-VEGF therapy; similarly those of clinical trials also vary depending on cancer type and the specific antiangiogenic therapy. Phase III studies have shown the benefits of VEGF-targeted therapies, including bevacizumab and sunitinib, either as single agents or in combination with chemotherapy. Nevertheless there is general agreement that antiangiogenic treatments are more effective in terms of increasing PFS than prolonging OS. Based on clear clinical benefit, although in the absence of a robust statistically significant increase in OS, VEGF-pathway inhibitors are currently the mainstay of therapy for renal cell carcinoma (RCC) [51, 52]. Because of this discrepancy between PFS and OS, and because antiangiogenic therapies typically exert their effects through increased tumour necrosis, how best to measure the clinical benefit of treatment remains controversial,. As reported, anti-VEGF agents induce ...
New blood vessel formation, or angiogenesis, is a critical hallmark of solid tumor growth and anti-angiogenic agents have become a vital component of current cancer treatment regimens. The appeal of anti-angiogenic therapy can be attributed to several advantages of targeting the endothelial cells that line blood vessels, rather than the tumor cells themselves. First, endothelial cells are directly exposed to circulating blood, facilitating drug delivery and enabling the use of high molecular weight therapeutics. Second, each vessel capillary supports hundreds of tumor cells. Third, endothelial cells are genetically stable and their ability to develop resistance may be limited. Finally, this type of therapy should be applicable to a wide variety of tumor types. Several anti-angiogenic agents that target the vascular endothelial growth factor (VEGF) pathway have been approved for the treatment of cancer. However, tumors can exploit alternative angiogenesis mechanisms when the VEGF pathway is ...
Phase I Study of Gemcitabine With Antiangiogenic Vaccine [angiogenesis inhibitor vaccine] Therapy Using Epitope Peptide Restricted to HLA [human leukocyte antigen]-A-2402 Derived From VEGFR2 [vascular endothelial grwoth factor receptor 2] in Patients With Unresectable, Locally Advanced, Recurrent or Metastatic Pancreatic Cancer ...
Figure 1a-d: Imaging results of a patient with glioblastoma undergoing bevacizumab therapy. First column: MRI (MP-RAGE with contrast enhancement); second column: 18F-FET-PET (parametric images scaled to mean uptake in a right temporal reference region); third column: image fusion. (A) scan prior to therapy 07/2010; (B) scan after 8 weeks of bevacizumab 09/2010; (C) scan after 16 weeks of bevacizumab 11/2010; (D) scan after re-irradiation with 20 Gy, 01/2011. Bevacizumab therapy was continued. For details, see ...
The evolving landscape of treatment for advanced gastric cancer and the role of anti-angiogenic therapy: implications from results of the INTEGRATE study
Historically, VEGFR-1 was assigned a role as a nonsignaling decoy receptor because of the low activity and embryonic dispensability of its tyrosine kinase function. More recently, its role has become more interesting because VEGFR-1 signaling has been reported both to promote (6, 7) and suppress (8) VEGF-A-driven angiogenesis. We report not only that PlGF-1 inhibits inflammatory CNV, extending the scope of VEGFR-1 function, but also what we believe is the unprecedented observation that VEGF-A itself can suppress angiogenesis. Multiple lines of evidence emerging from genetic ablation, antibody neutralization, and receptor-selective ligand activation all strongly support the thesis that the antiangiogenic action of VEGF-A is mediated by VEGFR-1. Previously, VEGF-A has been reported to reduce VEGF-E-induced VEGFR-2 tyrosine kinase phosphorylation in capillary endothelial cells in vitro, raising the provocative hypothesis that VEGF-A could limit its own angiogenic activity through VEGFR-1 (29). We ...
Purpose: Vascular endothelial growth factor (VEGF) is an angiogenic cytokine which is important in developmental blood vessel formation. In kidneys of embryonic to adult humans and mice, VEGF is detected in epithelial cells of the glomeruli and endothelial cells of glomeruli, tubules and peritubular capillaries. Some low birth weight (LBW) infants are known to have a decrease in nephron number and kidney size even after catch up growth. In order to find the potential therapy of infants with impaired renal development, we first generated the murine model, and investigated the effect of retinoic acid (RA). Materials and Methods: An angiogenesis inhibitor (SU1498) was injected subcutaneously to day 3 C57BL/6 newborn mice to create a model of arrested renal development. RA (2g/kg) was injected intraperitoneally for 10 consecutive days for the duration of renal development. Morphometric analysis of the renal cortex and glomerulus using light microscopic findings and electron microscopic examination ...
We investigated the anti-vascular activity of local hyperthermia (44 degrees C, 60 min) in s.c. BT4An rat gliomas, and the influence on tumour growth of hyperthermia and the anti-angiogenic compound batimastat (30 mg/kg i.p.). Heat-induced vascular damage was assessed in small (82 mm3) and large (171 mm3) tumours using confocal ...
Health,...Anti-angiogenesis drug prolonged progression-free survival study find...SATURDAY May 31 (HealthDay News) -- Adding the drug Avastin to chemot...Previous studies have found that adding Avastin (bevacizumab) to the c...Avastin is already approved for use in metastatic colon cancer non-sm...,Avastin,Added,to,Chemo,Helps,Women,With,Advanced,Breast,Cancer,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
We used semiautomated segmentation software to quantify total as well as the focal and diffuse components of leakage before and after anti-VEGF therapy. Anti-VEGF therapy effectively reduced total leakage as well as diffuse and focal leakage. However, the absolute and percent reduction in diffuse leakage was significantly greater than the reduction in focal leakage. These findings suggested that diffuse leakage is significantly more responsive to a moderate course of anti-VEGF therapy (approximately 5 injections on average). Numerous investigators have subtyped DME as diffuse or focal according to various criteria and using variable tools, which include biomicroscopy,21-29 fundus photography.23,24,27,28,30,31 FA,31-40 and OCT.41-44 To date, the utility of classifying DME based on FA has been limited by inherent subjectivity, multiple definitions and challenges in reproducibility.15,19 Fluorescein angiography has been used to distinguish diffuse and focal DME in numerous studies31,34,36,38,40 and ...
2-methoxyoestradiol (2-MeOE2) is a potent anti-angiogenic agent. Its 3- and 17-sulphamoylated derivatives have been demonstrated to induce G2-M cell cycle arrest and apoptosis in breast cancer cells in vitro as well as tumour regression in rats in vivo with greater potency than the parent oestrogen. To determine whether the anti-cancer properties of these derivatives can be synergistically enhanced with low-dose TNF-alpha co-treatment, we investigated the effects of these treatments in adult human fibroblasts and human umbilical vein endothelial cells (HUVECs). Treatment of fibroblasts with 0.1 microM 2-methoxyoestradiol-3,17-bis sulphamate (2-MeOE2bisMATE) but not 2-MeOE2 caused a reversible morphology change and induced G2-M arrest (from 12 to 33%) but not subsequent apoptosis. In contrast, treatment of HUVECs did not induce morphology change or G2-M arrest. Using a nucleosomal ELISA assay, we showed that TNF-alpha (20 ng/ml) combination treatment synergistically increases 0.1 microM 2-MeOE2bisMATE
Advanced imaging techniques may be able to distinguish which patients tumors will respond to treatment with antiangiogenic drugs and which will not.
TY - JOUR. T1 - A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. AU - Garlich, Joseph R.. AU - De, Pradip. AU - Dey, Nandini. AU - Jing, Dong Su. AU - Peng, Xiaodong. AU - Miller, Antoinette. AU - Murali, Ravoori. AU - Lu, Yiling. AU - Mills, Gordon B.. AU - Kundra, Vikas. AU - Shu, H. K.. AU - Peng, Qiong. AU - Durden, Donald L.. PY - 2008/1/1. Y1 - 2008/1/1. N2 - PTEN and the pan phosphoinositide 3-kinase (PI3K) inhibitor 2-(4-morpholinyl)-8-phenyl-4H-1benzopyran-4-one (LY294002) exert significant control over tumor-induced angiogenesis and tumor growth in vivo. The LY294002 compound is not a viable drug candidate due to poor pharmacologic variables of insolubility and short half-life. Herein, we describe the development and antitumor activity of a novel RGDS-conjugated LY294002 prodrug, termed SF1126, which is designed to exhibit increased solubility and bind to specific integrins within the tumor compartment, resulting ...
Usha Chakravarthy, MD, FRCS, FRCOphth, PhD, shares thoughts on recent research of systemic effects of anti-VEGF agents. She discusses clinical trials that monitor adverse events associated with anti-VEGF therapy and gives insight into the potential o…
In order for tumor cells to multiple and spread, they must develop their own blood supply through a process called angiogenesis. Angiogenesis inhibitor chemotherapy drugs work to stop or slow down this process, thereby controlling tumor growth. Metronomic chemotherapy is one example of angiogenesis inhibition treatment, which is becoming a popular treatment option for pets…
While it is true that the limitations of anti-VEGF therapy are becoming more evident as our experience with these agents increases, it is also undeniable that a subset of cancer patients treated with bevacizumab do show objective clinical responses and improved survival. However, we have yet to identify predictive biomarkers that have been validated in multiple, independent studies and can reliably distinguish patients who are likely to respond from those who will not. The identification of such biomarkers will be critical in harnessing the full potential of anti-VEGF therapy and in minimizing the rates of adverse side effects. The design and implementation of clinical trials based on proven, predictive biomarkers should allow for the enrichment of proper patient cohorts and facilitate the understanding of therapeutic mechanisms behind anti-VEGF therapy.. Several cytokines have been proposed in the literature as a possible predictive biomarker for anti-VEGF therapy. However, VEGF-A, the target ...
Results: 71 patients were treated, and the MTD was identified at the highest dose level (bevacizumab 15 mg/kg, bortezomib 1.3 mg/m2 ...
A free platform for explaining your research in plain language, and managing how you communicate around it - so you can understand how best to increase its impact.
Interference with the activity of TSP-1 and its antiangiogenic peptides by soluble GST-CD36 fusion proteins. Increasing concentrations of CD36 fusion proteins
The identification of patients likely to respond to antiangiogenic treatment has high priority. In this translational study, we analyzed the predictive value of the angiogenic couple, EGFL7 and miR126, in primary tumors from patients with mCRC treated with first-line chemotherapy and bevacizumab. The results indicated that the EGFL7 VA has a predictive value in this setting.. We analyzed two cohorts of patients with mCRC. The only difference between the two investigated cohorts was a higher fraction of patients with resected tumors compared with endoscopic biopsies in cohort 2. This difference, however, did not influence any of the clinical endpoints and, thus, allowed us to consider the two patient cohorts as one when analyzing the investigated parameters.. The present results demonstrate a significant difference in median EGFL7 VA in the tumor resections according to RR. Patients with low EGFL7 VA were more likely to respond to chemotherapy combined with anti-VEGF-A. With these findings, we ...
Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7-10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306). ...
Greenmedinfo.com - Natural Health Resource - The worlds most widely referenced, open access, natural medicine database, with 30,000+ study abstracts and growing daily
A concoction that meddles with the signs to structure fresh recruits vessels is alluded to as an angiogenesis inhibitor. Researchers have examined the impa..
A new review finds more evidence that the beleaguered cancer drug Avastin may harm patients. An analysis of previously published studies found that the drug, wh
AVASTIN prescription and dosage sizes information for physicians and healthcare professionals. Pharmacology, adverse reactions, warnings and side effects.
Hi there Teal Warriors I had my final chemo last week (first line 3c) and should be feeling relieved that it is over but I am worried about the side effects of taking Avastin over the next 9 months...
In addition to ID3, Kim et al. [72] also showed that the angiogenic inhibitor TSP-1 is decreased by 2.5-fold in response to PTTG1 overexpression in vitro ...
With the recent death of Judah Folkman there have been a number of articles touting the using of this drug in varied tumors. There is little doubt antiangiogenesis is an advance, but how much of an advance and can we afford it? Is two months survival benefit worth $50-$100,000 in expenditures for the drug alone?…
TY - JOUR. T1 - Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration. AU - Ciulla, Thomas A.. AU - Rosenfeld, Philip J. PY - 2009/5/1. Y1 - 2009/5/1. N2 - Lippincott Williams & Wilkins.. AB - Lippincott Williams & Wilkins.. KW - Anti-vascular endothelial growth factor therapy. KW - Bevacizumab. KW - Neovascularization. KW - Pegaptanib sodium. KW - Ranibizumab. UR - http://www.scopus.com/inward/record.url?scp=65549136672&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=65549136672&partnerID=8YFLogxK. U2 - 10.1097/ICU.0b013e328329d173. DO - 10.1097/ICU.0b013e328329d173. M3 - Article. C2 - 19381089. AN - SCOPUS:65549136672. VL - 20. SP - 166. EP - 174. JO - Current Opinion in Ophthalmology. JF - Current Opinion in Ophthalmology. SN - 1040-8738. IS - 3. ER - ...
Long-term suppression of RM with preservation of vision can be achieved with periodic intravitreal anti-VEGF therapy. In this study, treatment was well-tolerated and typically involved dose escalation (decreased time intervals and increased dose) based on objective findings over time. Objective findings of long-term suppression of macular edema, cotton-wool spots, and retinal hemorrhages suggest that periodic intravitreal anti-VEGF therapy effects a long-term disruption of the biologic process known as radiation vasculopathy. As in most noninfectious diseases, pharmacologic suppression offers delay from relatively acute organ failure.. Visual acuity outcomes after ophthalmic radiation therapy have been historically poor (13, 41). The most common cause of irreversible vision loss has been due to RM. For example, The Collaborative Ocular Melanoma Study (COMS) found that 45% of irradiated eyes were 20/200 or worse within 3 years after iodine-125 plaque therapy (this statistic includes eyes that did ...
While the efficacy and safety profile of ranibizumab in licensed indications has been demonstrated in multiple clinical trials,1-9 the safety profile of intravitreal anti-VEGF therapies in routine clinical practice remains less well established.. In a recent Medicare analysis (N=146 942), bevacizumab and ranibizumab were not associated with increased risks of mortality, myocardial infarction, bleeding or stroke compared with photodynamic therapy or pegaptanib.17 In a secondary analysis (21 815 intravitreal bevacizumab vs 19 026 ranibizumab), significantly lower risks for stroke (HR 0.78; 99% CI 0.64 to 0.96) and all-cause mortality (HR 0.86; 99% CI 0.75 to 0.98) were reported for ranibizumab compared with bevacizumab. Bevacizumab (Avastin, Roche, Basel, Switzerland) is not licensed for intraocular use or treatment of any ocular conditions.. Overall mortality with intravitreal bevacizumab compared with ranibizumab was also significantly increased in another Medicare claims analysis of ,77 000 ...
Studies comparing the effect of antiangiogenic agents targeting different angiogenic pathways are sparse. The purpose of this study was to compare the effect of properdistatin and sunitinib treatment in a preclinical model of malignant melanoma. Properdistatin is a small peptide derived from the thrombospondin-1 domain of the plasma protein properdin, and sunitinib is a tyrosine kinase inhibitor targeting several receptors including the vascular endothelial growth factor receptors. R-18 human melanoma xenografts growing in dorsal window chambers were treated with properdistatin, sunitinib, or vehicle. Parameters describing the morphology of tumor vasculature were assessed from high-resolution transillumination images, and BST (blood supply time; the time needed for arterial blood to flow from the main supplying artery to downstream microvessels) was assessed from first-pass imaging movies recorded after a bolus of fluorescence-labeled dextran had been administered intravenously. Tumor hypoxia was
The anti-emetic drug thalidomide is infamous for its teratogenic effects, which led to limb defects in more than 80% of children exposed in utero. However, thalidomide still has potentially positive value as an anti-inflammatory and anti-angiogenic compound for patients with some infectious diseases and cancer. Therapontos et al. show that the sensitivity of developing limbs to thalidomide-induced defects is dependent on the timing and type of blood vessel development. By examining the limb buds of chick embryos, they demonstrate that areas with rapid growth of immature blood vessels, such as the limb buds, are most susceptible to the anti-angiogenic effects of thalidomide, whereas mature vessels remain largely unaffected. The authors suggest that, since the effects of thalidomide vary depending on blood vessel maturity, this once-controversial compound may have therapeutic potential for preventing cancer-related angiogenesis.. ...
Corneal expression levels of the proinflammatory and pro(lymph)angiogenic cytokines IL-1β, TNFα, VEGF-A, VEGF-C, and VEGF-D were analyzed by real-time PCR after suture placement and treatment with serum eyedrops, bevacizumab eyedrops, or a combination of both. After 2 days of treatment, only bevacizumab affected IL-1β expression (serum mean of 95.6%, n.s.; bevacizumab mean of 74.3%, P , 0.01; and serum and bevacizumab mean of 96.4%, n.s.), whereas after 7 days of treatment, all treatment groups had significantly reduced IL-1β expression (serum mean of 48.4%, P , 0.001; bevacizumab mean of 58.9%, P , 0.001; and serum and bevacizumab mean of 53.2%, P , 0.001) (Fig. 5, top left). After 2 days of treatment, TNFα expression was significantly impaired only by bevacizumab (serum mean of 106.1%, n.s.; bevacizumab mean of 68.4%, P , 0.05; and serum and bevacizumab mean of 93.0%, n.s.), while after 7 days of treatment, the combination of serum and bevacizumab also showed considerable inhibition of ...
The dependence of tumor growth and metastasis on blood vessels makes tumor angiogenesis a rational target for therapy. Strategies have been pursued to inhibit neovascularization and to destroy existing tumor vessels, or both. These include direct targeting of endothelial cells, and indirect targeting by inhibiting the release of proangiogenic growth factors by cancer or stromal cells. Many patients benefit from antiangiogenic therapies; thus, development of noninvasive biomarkers of disease response and relapse is a crucial objective to aid in their management. A number of non-invasive tools are described with their potential benefits and limitations. We review currently available candidate biomarkers of anti-angiogenic agent effect. Including these markers into clinical trials may provide insight into appropriate dosing for desired biological effects, appropriate timing of additional therapy, and prediction of individual response. This has important consequences for the clinical use of angiogenesis
To investigate the effect of intravitreal bevacizumab and ranibizumab on wound tension and by histopathology during cutaneous wound healing in a rabbit model and to compare this effect to placebo intravitreal saline controls 1 and 2 weeks following i
Avastin eye medication, genentech avastin news, xeloda oxaliplatin avastin, avastin ovarian cancer trial 2008 and avastin use for macular degeneration. Folfox avastin regimen, avastin cost of therapy, avastin odac gbm and avastin and brain cancer or avastin drug class.
Inhibiting tumor growth by limiting angiogenesis can, in combination with chemotherapy, extend life expectancy in patients with certain malignancies and is being heavily pursued as a promising cancer therapy (1). There are several FDA-approved antiangiogenenic drugs currently used in the clinic to treat cancer and neovascular age-related macular degeneration (bevacizumab, pegaptanib, ranibizumab, sunitinib, and sorafenib) and many others under development. These agents inhibit angiogenesis by targeting the signaling pathways mediated by VEGF-A and potentially other VEGF family members, such as placental growth factor (PlGF), VEGF-B, VEGF-C, and VEGF-D. However, VEGF-A is probably the major positive regulator of blood vessel formation. Given the success of anti-VEGF therapy in multiple mouse models of cancer and in clinical trials, it is important to fully understand the mechanisms by which anti-VEGF treatment affects tumor angiogenesis at the cellular and molecular level. This will be ...
Significance of the rapid increase in GSH levels in the protective response to cadmium exposure through phosphorylated Nrf2 signaling in Jurkat T-cells. Free Radic. Biol. Med. 69, 58-66 (2014). 2. Nagasawa I, Kaneko A, Suzuki T, Nishio K, Kinoshita K, Shiro M, Koyama K. Potential anti-angiogenesis effects of p-terphenyl compounds from Polyozellus multiplex. Journal of natural products 77, 963-968 (2014). 3. Ogasawara Y, Imase M, Oda H, Wakabayashi H, Ishii K ...
We seek to determine whether Indirubins (IRs), a class of chemicals with relative selective inhibitory activity against glycogen synthase kinase-3 (GSK-3), exhi...
There is a very strong link between the vascularization of a tumour and the spread of the disease, both locally and to distant sites (Gimbrone et al., 1974, J. Natl. Cancer Inst. 52, 413-27; Muthukkaruppan et al, 1982, J. Natl. Cancer Inst. 69, 699-704; Ellis & Fiddler, 1995, Lancet 346, 388-9). A tumour becomes vascularized by a process known as angiogenesis. Tumour angiogenesis is initiated by the release of diffusible substances by the tumour, whereby neighbouring capillary vessels are stimulated to grow and eventually penetrate the tumour. Anti-angiogenesis has been proposed as a potential strategy for the treatment of cancer (Folkman, 1995, Nature Med. 1, 21-31; Harris et al, 1996, Breast Cancer Res. Treat. 38, 97-108). In this paper, a mathematical model of the development of the tumour vasculature is presented. By suitable manipulation of the model parameters, we simulate various anti-angiogenesis strategies and we examine the roles that haptotaxis and chemotaxis may play during the ...
SOUTH SAN FRANCISCO -- Genentech has given compounding pharmacies a months reprieve from its plan to stop selling them bevacizumab (Avastin), which they repackage as a low-cost alternative to ranibiz
Ethanol, RA and thalidomide treatments lead to major global gene expression changes in human EBs. (A) Histogram of the total number of up-regulated (blue) and d
Understanding of structural and functional characteristics of the vascular microenvironment in gliomas and the impact of antiangiogenic treatments is essential for developing better therapeutic strategies. Although a number of methods exist in which this process can be studied experimentally, no single noninvasive test has the capacity to provide information concerning both microvascular function and morphology. The purpose of present study is to demonstrate the feasibility of using a novel three-dimensional ?R2-based microscopic magnetic resonance angiography (3D ?R2-µMRA) technique for longitudinal imaging of tumor angiogenesis and monitoring the effects of antiangiogenic treatment in rodent brain tumor models. Using 3D ?R2-µMRA, a generally consistent early pattern of vascular development in gliomas was revealed, in which a single feeding vessel was visualized first (arteriogenesis), followed by sprouting angiogenesis. Considerable variability of the tumor-associated vasculature was then ...
Kaempferol offers been reported to reduce the risk of ovarian malignancy, but the mechanism is not completely understood. cells, and better characterized kaempferol toward chemoprevention. angiogenesis caused by ovarian malignancy cells, and the pathways involve regulation on HIF1- and ERR- gene expressions (Luo et al., 2009). Anti-angiogenesis is probably the most feasible strategy for current chemoprevention of ovarian cancers, given the fact that these early-stage tiny tumors cannot be successfully diagnosed but their continued development desperately depends on the establishment of a new blood vessel network (Bertl et al., 2006; Carmeliet et al., 2000). Tumor-free adults, on the other hand, have virtually zero need for angiogenesis in normal situations (Fotsis et al., 1993; Glade-Bender et al., 2003). Thus our findings about kaempferols anti-angiogenesis effects (Luo et al., 2009) become more relevant in this context. Nevertheless, the previously investigated pathways for kaempferol are not ...
Antiangiogenics have shown to be effective and safe anticancer agents in preclinical animal tumor models but have had mixed results in clinical trials with advanced disease. One possible explanation for the lack of efficacy in these clinical trials could be due to the bulky size of tumors in patients with stage III/IV disease. In theory, antiangiogenics would be predicted to be more effective in preventing smaller avascular tumors from activating the angiogenic switch and thus would be an ideal class of compounds for use in a chemopreventative setting. TM is a potent antiangiogenic compound that has completed numerous phase I/II trials for solid tumors. Results from these clinical trials showed that TM is very well tolerated with minimal adverse effects (6, 11-15). The attractive safety profile of TM suggests that it may be amendable to long-term use and thus be developed as a chemopreventative agent.. Recent work from our laboratory showed that TM significantly retards the development of ...
Almac Discovery today announced the licensing of its novel anti-angiogenic peptide ALM201 to Shin Poong Pharmaceutical Company Ltd for clinical development and marketing in South Korea. Shin Poong will make an undisclosed upfront payment and pay milestones and royalties as part of the deal. The Shin Poong programme in South Korea will run in parallel with Almac Discoverys own development programme in Europe.
Since VEGF is known to activate FAK - which plays a role in cellular signaling - in the endothelial cells that line pulmonary blood vessels, the researchers analyzed levels of the enzyme at the sites of induced vascular leakiness and found them to be elevated. "Blocking the activity of FAK in lung endothelial cells reduced both vascular permeability and the adhesion of metastatic cells to those tissues. Additional genetic experiments revealed that FAK produces these effects through increased local expression of the cellular adhesion molecule E-selectin," says Dai Fukumura, MD, PhD, of the Steele Lab, a co-senior author of the report.. Co-senior author Dan G. Duda, DMD, PhD, also of the Steele Lab, adds, "Anti-metastatic therapy is the ultimate frontier for cancer therapy, but existing treatments - both traditional chemotherapy and newer antiangiogenesis agents - have limited effectiveness in preventing the development of metastases. Our findings provide proof of principle that FAK inhibition is ...
Anti-angiogenesis occurs when new blood formation (angiogenesis) is stopped. Drugs that are used to stop angiogenesis are called anti-angiogenesis drugs.. Tags: A, Cancer Dictionary, Uncategorized. ...
Pazopanib is a novel antiangiogenic inhibitor of tyrosine kinases (TKIs) with high activity against vascular endothelial growth factor receptor (VEGFR1-3), platelet-derived growth factor receptor (PDGFRα+β), and c-Kit. Here we report on a patient with prostate cancer and type 2 diabetes whose glycemic control has been significantly improved with pazopanib during anticancer therapy and describe a potential mechanism of action.. The 73-year-old patient was diagnosed with prostate cancer in 1999 and underwent prostatectomy and radiotherapy, sequential hormonal therapies, and, in 2008, first line chemotherapy. Due to disease progression he was enrolled in a phase I trial with pazopanib (400 mg p.o. daily, day 1 to 21 every 3 weeks) in combination with epirubicine (75 mg/m2 i.v. q3w every 3 weeks). Type 2 diabetes was diagnosed when the patient was 69 years and weighed 103 kg (BMI 33.6 kg/m2). He was treated with glibenclamide resulting in moderate to poor glycemic control (A1C 7.5-10.9%).. In ...
One of the most recent methods that is being developed for the delivery of anti-angiogenesis factors to tumour regions in cancer sufferers is using genetically modified bacteria that are able to colonize solid tumors in vivo. This method involves genetically engineering bacterial species such as Clostridium, Bifidobacteria and Salmonella by adding the genes for anti-angiogenic factors such as endostatin or IP10 chemokine and removing any harmful virulence genes. A target can also be added to the outside of the bacteria so that they are sent to the correct organ in the body. The bacteria can then be injected into the patient and they will locate themselves to the tumor site, where they release a continual supply of the desired drugs in the vicinity of a growing cancer mass, preventing it from being able to gain access to oxygen and ultimately starving the cancer cells.[11] This method has been shown to work both in vitro and in vivo in mice models, with very promising results.[12] It is expected ...
Disclosed is a method for monitoring early treatment response of a cancer treatment comprising measuring by magnetic resonance spectroscopy (MRS), for example, proton MRS, the amount of Choline present in the tissue adjoining or surrounding the cancerous tissue before and after treatment; the treatment comprises administration of an angiogenesis inhibitor, for example, a VEGF inhibitor, whereby a decrease in the amount of Choline after treatment is indicative of a positive response. The decrease in the amount of Choline represents the decrease in the internal cell membrane as a result of down regulation of the organelles and their secretory granules and their transport vesicles. Disclosed also is a method for determining effectiveness of an angiogenesis inhibitor in the treatment of cancer. Also disclosed are methods of monitoring early treatment response in diseases where an angiogenesis effector, i.e., an inhibitor or promoter of angiogenesis, is employed. Also disclosed is a method for monitoring
Sometimes called antiangiogenic therapy, this treatment may prevent the growth of cancer by blocking the formation of new blood vessels.
Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association. ...
Life Enhancement Products, an innovative manufacturer of nutritional supplements with unique formulations for memory enhancement, blood sugar maintenance, thyroid support, weight control, gastrointestinal support, and more.
Current antiangiogenic therapy is limited by its cytostatic property, scarce drug delivery to the tumor, and side toxicity. To address these limitations, we unveiled the role of ZEB1, a tumor endothelium-enriched zinc-finger transcription factor, during tumor progression. We discovered that the patients who had lung adenocarcinomas with high ZEB1 expression in tumor endothelium had increased prevalence of metastases and markedly reduced overall survival after the diagnosis of lung cancer. Endothelial ZEB1 deletion in tumor-bearing mice diminished tumor angiogenesis while eliciting persistent tumor vascular normalization by epigenetically repressing TGF-β signaling. This consequently led to improved blood and oxygen perfusion, enhanced chemotherapy delivery and immune effector cell infiltration, and reduced tumor growth and metastasis. Moreover, targeting vascular ZEB1 remarkably potentiated the anticancer activity of nontoxic low-dose cisplatin. Treatment with low-dose anti-programmed cell ...
Ive decided to go off of chemo until Jan 7. The Avastin was making me have chemo brain and neuropathy and I decided I simply dont want to live that way. Plus, this recent information out about Avastin promoting the formation of new, "satellite" tumors really hit home. While I was pleased that the Avastin took care of my swelling, I did, indeed, get a new tumor while on it. I told my new NO that we have never really given the supplements, especially the CO (cannabis oils), a fair chance because Ive always been on a chemo at the same time. Avastin, for example, somewhat shuts down the blood brain barrier as these publications attest. He agreed I could give the supplements and CO a fair shot. Its a bit scary ...
Standard anticancer chemotherapy has been historically thought to act through direct killing of tumor cells. lymphodepletion followed by rebound replenishment of immune cell pools; (iii) by subverting tumor-induced immunosuppressive mechanisms and (iv) by exerting direct or indirect stimulatory effects on immune effectors. Among the indirect ways of immune cell activation, some buy VTP-27999 HCl cytotoxic drugs have been shown to induce an immunogenic type of cell death in tumor cells, producing in the emission of specific signals that trigger phagocytosis of cell debris and promote the maturation of dendritic cells, ultimately producing in the induction of potent antitumor responses. Here, we provide an considerable overview of the multiple immune-based mechanisms exploited by the most generally employed cytotoxic drugs, with the final aim of identifying prerequisites for optimal combination with immunotherapy strategies for the development of more buy VTP-27999 HCl effective treatments against ...
β3-Integrin-knockout mice exhibit a complex phenotype that includes enhanced pathological angiogenesis. However, as mentioned above, β3-integrin is expressed by a diverse set of cells, and the described phenotype must arise from the integration of its pattern of expression. Although interesting, this biological integration makes it difficult to distinguish cell autonomous effects of β3-integrin. Our studies have addressed, for the first time to our knowledge, the specific contribution that endothelial β3-integrin makes to tumor growth and angiogenesis. Our findings have profound implications for targeting the endothelial-specific expression of β3-integrin to inhibit tumor angiogenesis, a strategy that is growing in popularity with the maturation of nanotechnology.38. Consistent with our findings in β3-knockout animals,10 the depletion of endothelial β3-integrin did not alter the structure of established tumor vessels (Online Figure IA and Online Figure VIA). Sprouting angiogenesis ...
May 16, 2008 - Genentech, Inc. (NYSE DNA) today provided an overview of several clinical studies of Avastin(R) in multiple types of cancer that will be presente
Relative quantification was done using Ct measurements R547 741713-40-6 on SYBR Green based fluores cence readings with HPRT as a housekeeping gene. Mea surements were done in triplicate. Flow cytometry Protein expression of receptors on the tumor cell sur face was determined by flow cytometry. Cells were harvested using Accutase solution after 24 hours of normoxia, hypoxia and hyp oxia with bevacizumab treatment. Cells were labeled for Neuropilin1 with CD304 and VEGFR2 with CD309 APC conjugated antibodies and measured by a BD FACS Canto II flow cytometer. HUVEC were used Inhibitors,Modulators,Libraries as a control. Analysis was done using FlowJo software to determine the percentages of positive cells. Results represent averaged percentages from two biological repetitions. Propidium iodide stained cells were prepared by fixing the cells in 80% ice cold ethanol for up to 48 hours.. Cells were then washed with PBS and resuspended and incubated for 30 minutes in 38 mM sodium citrate, 24 ug ml ...
Summary: This is a long post so here is a short summary: Omega-3 fatty acids have anti-inflammatory, antiproliferative, proapoptotic, antiangiogenetic, anti-invasion, and antimetastatic properties. Because Omega-3 fatty acids are pushing out of the cancer cells the glutathione much needed for the cancer cell survival, Omega-3 fatty acids can be also combined with chemo and with that increase or enable ...
Bevacizumab is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Bevacizumab is used to treat a certain type of brain tumor, and certain types of cancers of the kidney, lung, colon, rectum, cervix, ovary, or fallopian tube. Bevacizumab is also used to treat cancer of the membrane...
View mouse Baiap2 Chr11:119942763-120006782 with: phenotypes, sequences, polymorphisms, proteins, references, function, expression
New research indicates that a new way of analyzing data acquired in MR imaging appears to be able to identify whether or not tumors are responding to anti-angiogenesis therapy.
Accumulating evidence is cause for concern and underscoring the need for more research evaluating the safety of anti-VEGF injections for ROP, according to Robert L. Avery, MD.
Sigma-Aldrich offers abstracts and full-text articles by [Yoo Bin Kwon, Chang Deok Kim, Bo Joong Kim, Min-Young Kim, Chang Seo Park, Tae-Jin Yoon, Young-Joon Seo, Ki-Beom Suhr, Jang-Kyu Park, Jeung-Hoon Lee].
After the FDA revoked its approval of Avastin for the treatment of metastatic breast cancer, the drug maker says it will initiate new trials.
The most frequent ocular adverse events with VEGF Trap - but clinically important differences regarding systemic adverse events. VEGF injection followed by PDT by meta, term safety effects. Vitreal ranibizumab
The combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) improved progression-free survival compared with sunitinib (Sutent, Pfizer) as ...
We eventually learned that the in-tandem radio- and chemotherapy had killed a significant portion of the second mass, which was good news. But the third mass appeared (we think) after the therapeutic regimen was finished. Instead of continuing the standard treatment, which would have been several months of chemo alone, we moved to stronger, second-line therapy. Mom is currently on Avastin, which became a standard second-line therapy for GBM only as of this past May. Avastin is taken through intravenous infusion; it works by stopping the growth of new blood vessels and helps to shrink the blood vessels feeding the tumors. Some patients experience a halting of tumor growth; luckier patients enjoy actual tumor shrinkage. A large percentage of patients, however-- 30-50%-- do not respond to Avastin at all. On October 30, we learned that the first two masses responded to the Avastin by shrinking, but the third mass has grown unchecked. Mom is therefore starting yet another type of chemotherapy on top ...
According to pSivida, the ability to control the duration of sustained delivery of antibodies through pore size is significant. By varying the pore size, which controls the release rate of antibodies loaded into Tethadur, sustained delivery of antibodies such as bevacizumab could be permitted ...
The value of bevacizumab in the treatment of many cancers has been questioned, given that it has been approved mostly on the basis of progression-free, and not overall, survival benefits.
This single arm genetic substudy of MO19390 will test the hypothesis that there is a positive relationship between mRNA BRCAI levels and the response to
PURPOSE To investigate the efficacy of intravitreal injection of anti-vascular endothelial growth factor agents for Stage 4 retinopathy of prematurity. METHODS Retrospective case series study. The medical records of patients receiving intravitreal injection of anti-vascular endothelial growth factor agents for Stage 4 retinopathy of prematurity from January 2007 to May 2012 in Taipei Veterans General Hospital were reviewed. RESULTS A total of 13 eyes of 7 patients (3 boys and 4 girls) with Stage 4 retinopathy of prematurity were included. The mean gestational age and birth weight were 27.6 ± 2.6 weeks (range, 24.5-30.5 weeks) and 893.1 ± 293.2 g (range, 550-1422 g), respectively. The mean age at the time of injection was 38.2 ± 1.9 weeks (range, 36.0-41.5 weeks) postmenstrual age, and the mean follow-up period was 37.8 ± 19.5 months (range, 11.0-67.5 months). The active neovascularization regressed rapidly, and the anatomical outcomes were favorable in all patients. One eye developed recurrent
A topical, slow-release anti-angiogenic drug for treating eye diseases Ofra Benny, PhD and Robert DAmato, MD, PhD, Vascular Biology Program. This projects aim is to develop Lodamin as a drug for ophthalmology uses. Lodamin is a novel oral anti-angiogenic drug and a non-toxic derivative of TNP-470 with preclinical activity in oncology.. Angiogenesis-related eye diseases, such as diabetic retinopathy and macular degeneration are common. Effective anti-angiogenic therapies aim to delay the progression of these ophthalmic diseases and prevent vision loss. Currently there are no antiangiogenic drugs approved for corneal neovascularization but only indirect angiogenesis inhibitors such as steroids and immunosuppressants. For retinal angiogenesis-related diseases, such as Age-Related Macular Degeneration (AMD), the only antiangiogenic therapies available are based on targeting a single growth factor: Vascular Endothelial Growth Factor (VEGF). Contrary to these available treatments, Lodamin inhibits ...
Retinal Functional Changes Measured by Microperimetry after Intravitreal Ranibizumab Injection and Sulfotanshinone Sodium Injection for Macular Edema Secondary to Retinal Vein Occlusion. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
TY - JOUR. T1 - Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. AU - Conley, Sarah J.. AU - Gheordunescu, Elizabeth. AU - Kakarala, Pramod. AU - Newman, Bryan. AU - Korkaya, Hasan. AU - Heath, Amber N.. AU - Clouthier, Shawn G.. AU - Wicha, Max S.. PY - 2012/2/21. Y1 - 2012/2/21. N2 - Antiangiogenic therapy has been thought to hold significant potential for the treatment of cancer. However, the efficacy of such treatments, especially in breast cancer patients, has been called into question, as recent clinical trials reveal only limited effectiveness of antiangiogenic agents in prolonging patient survival. New research using preclinical models further suggests that antiangiogenic agents actually increase invasive and metastatic properties of breast cancer cells. We demonstrate that by generating intratumoral hypoxia in human breast cancer xenografts, the antiangiogenic agents sunitinib and bevacizumab increase the population of cancer stem cells. In ...
Use of nepafenac (Nevanac®) in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injections Eric Chen, Matthew S Benz, Richard H Fish, David M Brown, Tien P Wong, Rosa Y Kim, James C MajorRetina Consultants of Houston, The Methodist Hospital, Houston, TX, USAPurpose: The purpose of this study is to determine the efficacy of combining topical nepafenac with monthly intravitreal injections of ranibizumab or bevacizumab in the treatment of recalcitrant exudative macular degeneration.Methods: This was a retrospective, consecutive case series of patients with exudative macular degeneration requiring maintenance therapy of antivascular endothelial growth factor (anti-VEGF) injections at least every 6 weeks, who were started on topical nepafenac. Despite frequent anti-VEGF dosing, all patients included in the study had persistence of any combination of the following: intraretinal cysts, subretinal fluid, and/or pigment epithelial
The feasibility of photoacoustic microscopy (PAM) for evaluation of angiogenesis inhibitor was investigated on a chick embryo model in vivo. Different concentrations of the angiogenesis inhibitor, Sunitinib, were applied to the chorioallantoic membrane (CAM) of the chick embryos. Imaging of microvasculature in embryo CAMs was acquired using a laser-scanning PAM system; while the optical microscopy (OM) capturing the microvascular images of the same set of CAMs for comparison served as a gold standard for validating the results from PAM. The microvascular density as a function of applied Sunitinib concentration has been quantified in both PAM and OM images. The results from these two modalities have a good agreement, suggesting that PAM could provide an unbiased quantification of microvascular density for objective evaluation of anti-angiogenesis medication. In comparison with conventional OM which enables only two-dimensional enface imaging, PAM is capable of three-dimensional analysis of ...
Purpose.: Anti-VEGF-A antibody (Ab) (e.g., bevacizumab, ranibizumab) is widely used as a treatment against retinal angiogenesis and edema. The purpose of this study was to evaluate whether intravitreal anti-VEGF Ab injection modulates inflammatory cells in retinal angiogenesis. Methods.: To investigate whether intravitreal bevacizumab injections affect the number of inflammatory cells in proliferative diabetic retinopathy (PDR) membranes in patients, immunohistochemical staining with CD45 Ab (pan-leukocyte marker) was performed using the surgically obtained membranes in pars plana vitrectomy with or without pretreatment with bevacizumab. To check whether anti-VEGF-A Ab affects leukocytes going in and out of blood vessels during retinal angiogenesis, the authors performed their novel leukocyte transmigration assay and CD45 immunostaining in a mouse model of oxygen-induced retinopathy (OIR). Results.: The authors new imaging approach revealed that intravitreal injection of anti-VEGF-A Ab blocks ...
PURPOSE To evaluate the effects of intravitreal bevacizumab and ranibizumab treatments in retinal angiomatous proliferation (RAP). METHODS Fifty patients affected by RAP were randomly assigned either to intravitreal bevacizumab injection (IVBI) or intravitreal ranibizumab injection (IVRI). After a loading phase including three consecutive monthly injections, the retreatment was administered in cases of persistent RAP. The primary outcome measures were the mean changes in BCVA between the two treatment groups, and the proportion of eyes gaining 1 and 3 lines at the end of the follow-up. Secondary outcomes included central macular thickness (CMT) changes and progression to more advanced stages of RAP. RESULTS Fifty patients affected by stage 1 and 2 RAP were recruited. Twenty-six and 24 patients received IVBI and IVRI, respectively. At the baseline, mean best corrected visual acuity (BCVA) values were 0.59 ± 0.21 (LogMAR ± SD, approximately corresponding to 20/80 Snellen Equivalent-SE) in IVBI group
BioAssay record AID 52868 submitted by ChEMBL: Compound was tested for antiangiogenic activity in chick embryo chorioallantoic membrane (CAM) assay system at 10 ug/egg dose; No of CAM avascular/total=4/16(25%).
Purpose: To describe the clinical characteristics and outcome of eyes with extrafoveal polypoidal choroidal vasculopathy (PCV) treated with argon laser. Design: Prospective cohort, noninterventional study. Methods: A prospective study of Asian patients with extrafoveal PCV, confirmed on indocyanine green angiography and treated with argon laser with and without anti-vascular endothelial growth factor (VEGF) therapy. Patients were followed-up over 12 months with visual, angiographic, and structural outcomes recorded. Results: Of the 93 eyes with PCV at baseline, 33 eyes (35.5%) in 31 patients had extrafoveal involvement and were treated with argon laser. Foveal involvement with fluid or blood at baseline was apparent in 23 eyes (69.7%), despite the extrafoveal location of 1 or more polyps. Of these 33 eyes, 12 (36.4%) also received anti-VEGF injections (median, 2.5 injections) over the 12-month period. Two eyes received photodynamic therapy rescue during subsequent follow-up and were excluded for ...
TY - JOUR. T1 - Angiogenic activity of multiple myeloma endothelial cells in vivo in the chick embryo chorioallantoic membrane assay is associated to a down-regulation in the expression of endogenous endostatin. AU - Mangieri, Domenica. AU - Nico, Beatrice. AU - Benagiano, Vincenzo. AU - De Giorgis, Michela. AU - Vacca, Angelo. AU - Ribatti, Domenico. PY - 2008/6. Y1 - 2008/6. N2 - We have attempted a fine characterization of the angiogenic response induced by multiple myeloma endothelial cells (MMEC) by using the chick embryo chorioallantoic membrane (CAM) assay and by reverse transcriptase-polymerase chain reaction (RT-PCR). Results showed that in the CAM assay MMEC induced an angiogenic response comparable to that of a well-known angiogenic cytokine, namely fibroblast growth factor-2 (FGF-2), while RT-PCR demonstrated that the expression of endostatin mRNA detected in MM treated CAM was significantly lower respect to control CAM. These data suggest that angiogenic switch in MM may involve ...
The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions Biljana Ivanovska Adjievska,1 Salih Boskurt,1 Nikola Orovcanec,2 Vesna Dimovska-Jordanova3 1Department for Posterior Segment, European Eye Hospital, Skopje, Republic of Macedonia; 2Department for Medical Statistics, Institute for Epidemiology and Medical Statistics, Medical Faculty, Skopje, Republic of Macedonia; 3Department for Retinal Diseases, University Clinic for Eyes Diseases, St Cyril and Methodius University, Skopje, Republic of Macedonia Aim: We aimed to evaluate the 1-year efficacy and safety of low-frequency intravitreal bevacizumab in the treatment of macular edema due to retinal vein occlusions (RVOs).Methods: The study comprised an interventional prospective study of patients with macular edema due to central retinal vein occlusion (CRVO) or branch retinal vein occlusion, followed for 12 months. Treatment-naïve patients with reduced best-corrected visual acuity (BCVA) and
Learn about LUCENTIS® (ranibizumab injection) in regards to Wet AMD treatment here. INDICATIONS LUCENTIS® (ranibizumab injection) is indicated for the treatment of patients with: Neovascular (wet) age-related macular degeneration (wAMD) Macular edema following retinal vein occlusion (RVO) Diabetic macular edema (DME) Diabetic retinopathy (DR) Myopic choroidal neovascularization (mCNV) IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS LUCENTIS is contraindicated in patients with ocular or periocular infections or known hypersensitivity to ranibizumab or any of the excipients in LUCENTIS. WARNINGS AND PRECAUTIONS Intravitreal injections, including those with LUCENTIS, have been associated with endophthalmitis and retinal detachment. Proper aseptic injection technique should always be utilized when administering LUCENTIS. Patients should be monitored following the injection to permit early treatment, should an infection occur. Increases in intraocular pressure (IOP) have been noted both pre-injection and

Angiogenesis inhibitor - WikipediaAngiogenesis inhibitor - Wikipedia

Angiogenesis Inhibitors for Cancer - from The Angiogenesis Foundation, 23 June 2009. *Angiogenesis Inhibitors for Eye Disease ... An angiogenesis inhibitor is a substance that inhibits the growth of new blood vessels (angiogenesis). Some angiogenesis ... and are thus destroyed by angiogenesis inhibitors.[28] Angiogenesis inhibitors are also used as treatment for the wet form of ... downregulate angiogenesis stimulators and inhibit cell migration of endothelial cells. IL-12. stimulate angiogenesis inhibitor ...
more infohttps://en.wikipedia.org/wiki/Angiogenesis_inhibitor

Angiogenesis Inhibitors | CancerIndexAngiogenesis Inhibitors | CancerIndex

Home > Treatments > Biological Therapies > Angiogenesis Inhibitors Angiogenesis Inhibitors. Angiogenesis is the process which ... PubMed Central search for free-access publications about Angiogenesis Inhibitors. MeSH term: Angiogenesis Inhibitors. US ... Inhibitors work in different ways: * by blocking angiogenesis growth factors (substances, such as VEGF, which promote the ... Many synthetic inhibitors of angiogenesis have not only come into force but also resulted in some severe adverse effects. ...
more infohttp://www.cancerindex.org/Angiogenesis_Inhibitors

Angiogenesis Inhibitors - Angiogenesis | Sigma-AldrichAngiogenesis Inhibitors - Angiogenesis | Sigma-Aldrich

Potent inhibitor of angiogenesis and tumor growth in vitro and in vivo; specifically inhibits endothelial cell proliferation.. ... Endostatin is a potent inhibitor of angiogenesis and tumor growth in vitro and in vivo; specifcally inhibits endothelial cell ... However, it does not have an overall impact on wound healing. As it is a potent inhibitor of angiogenesis, it also strongly ... A specific inhibitor of endothelial cell growth and angiogenesis. More active relative to kringles 1-4. Studies with ...
more infohttps://www.sigmaaldrich.com/life-science/cell-biology/cell-biology-products.html?TablePage=14938463

Angiogenesis Inhibitors | Johns Hopkins Medicine Health LibraryAngiogenesis Inhibitors | Johns Hopkins Medicine Health Library

Many other angiogenesis inhibitors are now being studied as well.. Angiogenesis inhibitors have different side effects from ... But angiogenesis inhibitors only prevent new blood vessels from forming. The side effects from angiogenesis inhibitors are ... Scientists have studied the effect of angiogenesis inhibitors on certain kinds of tumors and cells. Several of the angiogenesis ... What are angiogenesis inhibitors and how do they work?. A chemical that interferes with the signals to form new blood vessels ...
more infohttps://www.hopkinsmedicine.org/healthlibrary/conditions/adult/prostate_health/angiogenesis_inhibitors_85,P01246

Angiogenesis Inhibitors | GreenMedInfo | Pharmacological ActionAngiogenesis Inhibitors | GreenMedInfo | Pharmacological Action

Pharmacological Actions : Angiogenesis Inhibitors, Anti-Inflammatory Agents. Additional Keywords : Angiogenesis Inhibitors, ... Pharmacological Actions : Angiogenesis Inhibitors, Hypoxia-inducible factor-1 (HIF-1) inhibitor, NF-kappaB Inhibitor, Vascular ... Pharmacological Actions : Angiogenesis Inhibitors, Antiproliferative , Apoptotic. Additional Keywords : Angiogenesis Inhibitors ... Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A Inhibitor, Vascular Endothelial Growth Factor C Inhibitor, ...
more infohttp://www.greenmedinfo.com/pharmacological-action/angiogenesis-inhibitors

A New Angiogenesis Inhibitor | Science SignalingA New Angiogenesis Inhibitor | Science Signaling

... αPIGF inhibited tumor angiogenesis and lymphangiogenesis, as well as tumor recruitment of proangiogenic macrophages. αPIGF ... inhibitor-resistant tumors without affecting healthy vessels. Cell 131, 463-475 (2007). [PubMed] ... is not required for normal development and maintenance of the vasculature but has been implicated in pathological angiogenesis ...
more infohttp://stke.sciencemag.org/content/2007/411/tw398

Angiogenesis-inhibitors for metastatic thyroid cancer | CochraneAngiogenesis-inhibitors for metastatic thyroid cancer | Cochrane

Angiogenesis-inhibitors for metastatic thyroid cancer. There is currently no reliable evidence from randomized controlled ... To evaluate the benefits and risks of angiogenesis-inhibitors for metastatic thyroid cancer when given alone, or in combination ... Tan A, Xia N, Gao F, Mo Z, Cao Y. Angiogenesis-inhibitors for metastatic thyroid cancer. Cochrane Database of Systematic ... We planned to include randomized controlled trials that compared angiogenesis-inhibitors with other treatments, no treatment, ...
more infohttp://www.cochrane.org/CD007958/ENDOC_angiogenesis-inhibitors-for-metastatic-thyroid-cancer

Angiogenesis Inhibitor Works in Macular Edema | Medpage TodayAngiogenesis Inhibitor Works in Macular Edema | Medpage Today

Patients with macular edema related to retinal vein occlusion had significant improvement in vision when treated with ranibizumab (Lucentis) in each of two dosages, randomized clinical trials showed.
more infohttps://www.medpagetoday.com/ophthalmology/generalophthalmology/16301

Angiogenesis Inhibitors - AHealthyMe - Blue Cross Blue Shield of MassachusettsAngiogenesis Inhibitors - AHealthyMe - Blue Cross Blue Shield of Massachusetts

Angiogenesis Inhibitors. What is angiogenesis?. Angiogenesis is the formation of new blood vessels. The process is controlled ... Many other angiogenesis inhibitors are now being studied as well.. Angiogenesis inhibitors have different side effects from ... But angiogenesis inhibitors only prevent new blood vessels from forming. The side effects from angiogenesis inhibitors are ... Scientists have studied the effect of angiogenesis inhibitors on certain kinds of tumors and cells. Several of the angiogenesis ...
more infohttp://www.ahealthyme.com/Library/DiseasesConditions/Adult/Kidney/85,P01246

Angiogenesis Inhibitors - AHealthyMe - Blue Cross Blue Shield of MassachusettsAngiogenesis Inhibitors - AHealthyMe - Blue Cross Blue Shield of Massachusetts

Angiogenesis Inhibitors. What is angiogenesis?. Angiogenesis is the formation of new blood vessels. The process is controlled ... Many other angiogenesis inhibitors are now being studied as well.. Angiogenesis inhibitors have different side effects from ... But angiogenesis inhibitors only prevent new blood vessels from forming. The side effects from angiogenesis inhibitors are ... Scientists have studied the effect of angiogenesis inhibitors on certain kinds of tumors and cells. Several of the angiogenesis ...
more infohttp://www.ahealthyme.com/Library/DiseasesConditions/Adult/Gynecological/85,P01246

Angiogenesis Inhibitors | SCBT - Santa Cruz BiotechnologyAngiogenesis Inhibitors | SCBT - Santa Cruz Biotechnology

View and select products within our Angiogenesis Inhibitors category available for immediate purchase. ... Angiogenesis Inhibitors. Santa Cruz Biotechnology now offers a broad range of Angiogenesis Inhibitors. Angiogenesis Inhibitors ... A potent inhibitor of angiogenesis, a vimentin and proteasome inhibitor. 5119-48-2. sc-200381. sc-200381A. 1 mg. 10 mg. $115.00 ... An inhibitor of PDGFR-β, Flk-1, and angiogenesis. 168836-03-1. sc-205984. sc-205984A. 1 mg. 5 mg. $48.00. $200.00. 0. ...
more infohttps://www.scbt.com/scbt/browse/Angiogenesis-Inhibitors/_/N-1ti74hm

Global Cancer Angiogenesis Inhibitors Market & Clinical Pipeline InsightGlobal Cancer Angiogenesis Inhibitors Market & Clinical Pipeline Insight

6. Classification of Angiogenesis Inhibitors. 6.1 Direct Endogenous Inhibitors of Angiogenesis. 6.2 Indirect Inhibitors of ... Global Cancer Angiogenesis Inhibitors Clinical Pipeline: 146 Drugs. - Marketed Cancer Angiogenesis Inhibitors Drugs: 11 Drugs ... 9. Global Angiogenesis Inhibitors Market overview. 9.1 Current Market Scenario. 9.2 Global Cancer Angiogenesis Inhibitors ... One of the major segments of cancer therapy is occupied by the angiogenesis inhibitors. The market for angiogenesis inhibitors ...
more infohttps://www.researchandmarkets.com/reports/3821716/global-cancer-angiogenesis-inhibitors-market-and

Rifampicin as an Oral Angiogenesis Inhibitor Targeting Hepatic Cancers | Cancer ResearchRifampicin as an Oral Angiogenesis Inhibitor Targeting Hepatic Cancers | Cancer Research

... an endogenous angiogenesis inhibitor known to down-regulate a variety of growth- and angiogenesis-related genes in a wide range ... and angiogenesis-associated genes in the endothelium because this phenomenon is induced by a potent angiogenesis inhibitor, ... Rifampicin as an Oral Angiogenesis Inhibitor Targeting Hepatic Cancers. Masayoshi Shichiri, Nozomi Fukai, Yutaka Kono and ... Rifampicin as an Oral Angiogenesis Inhibitor Targeting Hepatic Cancers. Masayoshi Shichiri, Nozomi Fukai, Yutaka Kono and ...
more infohttp://cancerres.aacrjournals.org/content/69/11/4760.long

Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors - Full Text View - ClinicalTrials.govStudy to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors - Full Text View - ClinicalTrials.gov

Drug: usage oral angiogenesis inhibitor Drug: stop oral angiogenesis inhibitor Phase 4 ... Angiogenesis Inhibitors. Angiogenesis Modulating Agents. Growth Substances. Physiological Effects of Drugs. Growth Inhibitors. ... Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors. The safety and scientific validity of this study is ... However, angiogenesis inhibitors have a rather cytostatic than cytotoxic effect compared to chemotherapeutics, as a result of ...
more infohttps://clinicaltrials.gov/show/NCT00777504

Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470).  - PubMed - NCBICytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). - PubMed - NCBI

Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470).. Kusaka M1, Sudo K, ...
more infohttps://www.ncbi.nlm.nih.gov/pubmed/8297716?dopt=Abstract

Retinoic acid decreases apoptosis in mice treated with an angiogenesis inhibitorRetinoic acid decreases apoptosis in mice treated with an angiogenesis inhibitor

... Ju SY , Cho KA , Ryu KH , Woo SY , Park EA ... METHODS: SU1498, a VEGFR2 inhibitor or vehicle was given to three-day-old mice. Subsequent retinoic acid or vehicle injection ...
more infohttps://koreamed.org/article/0044KJP/2008.19.1.54

Emerging Medicine: Angiogenesis Inhibitor: What Does Athletes Foot Have to Do with Angiogenesis?Emerging Medicine: Angiogenesis Inhibitor: What Does Athlete's Foot Have to Do with Angiogenesis?

Emerging Medicine: Angiogenesis Inhibitor What Does Athletes Foot Have to Do with Angiogenesis?. ... Angiogenesis Inhibitor: What Does Athletes Foot Have to Do with Angiogenesis? ... The researchers had screened a library of known drugs in an earlier study looking for inhibitors of angiogenesis and found that ... The researchers state that the mTOR inhibitor rapamycin and its analogue temsirolimus both inhibit tumor angiogenesis in vivo ...
more infohttp://www.life-enhancement.com/magazine/article/2263-emerging-medicine-angiogenesis-inhibitor-what-does-athletes-foot-have-to-do-with-angiogenesis

Cartilage-derived angiogenesis inhibitor - WikipediaCartilage-derived angiogenesis inhibitor - Wikipedia

A cartilage-derived angiogenesis inhibitor is an angiogenesis inhibitor produced from cartilage. Examples include the peptide ... a cartilage-derived angiogenesis inhibitor: in vitro and in vivo effects on human endothelial cells and on pancreatic cancer". ... March 2004). "Suppression of T cell responses by chondromodulin I, a cartilage-derived angiogenesis inhibitory factor: ...
more infohttps://en.wikipedia.org/wiki/Cartilage-derived_angiogenesis_inhibitor

Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib | Molecular Cancer...Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib | Molecular Cancer...

Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. Jie Ma and David J. ... In summary, the angiogenesis inhibitor axitinib is shown to modulate the antitumor activity of metronomic cyclophosphamide in ... The promising but still limited efficacy of angiogenesis inhibitors as monotherapies for cancer treatment indicates a need to ... Nieder C, Wiedenmann N, Andratschke N, Molls M. Current status of angiogenesis inhibitors combined with radiation therapy. ...
more infohttp://mct.aacrjournals.org/content/7/1/79

OSA | Photoacoustic microscopy: a potential new tool for evaluation of angiogenesis inhibitorOSA | Photoacoustic microscopy: a potential new tool for evaluation of angiogenesis inhibitor

Photoacoustic microscopy: a potential new tool for evaluation of angiogenesis inhibitor Sung-Liang Chen, Joseph Burnett, Duxin ... The feasibility of photoacoustic microscopy (PAM) for evaluation of angiogenesis inhibitor was investigated on a chick embryo ... Chick embryos are treated by angiogenesis inhibitor, Sunitinib, with different concentrations. From left to right: the 0.9% ... Different concentrations of the angiogenesis inhibitor, Sunitinib, were applied to the chorioallantoic membrane (CAM) of the ...
more infohttps://www.osapublishing.org/boe/abstract.cfm?uri=boe-4-11-2657

Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung...Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung...

Angiogenesis is critical for tumor growth and metastasis, and several inhibitors of angiogenesis are currently in clinical use ... Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung ... Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung ... Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung ...
more infohttps://www.ncbi.nlm.nih.gov/pubmed/21436589?dopt=Abstract

Brain angiogenesis inhibitor 1 (BAI1) is a pattern recognition receptor that mediates macrophage binding and engulfment of Gram...Brain angiogenesis inhibitor 1 (BAI1) is a pattern recognition receptor that mediates macrophage binding and engulfment of Gram...

BAI1 (brain-specific angiogenesis inhibitor 1) is a member of the so-called adhesion-type family of 7-transmembrane receptors ( ... Brain angiogenesis inhibitor 1 (BAI1) is a pattern recognition receptor that mediates macrophage binding and engulfment of Gram ... Brain angiogenesis inhibitor 1 (BAI1) is a receptor that recognizes apoptotic cells through its conserved type I thrombospondin ... Brain angiogenesis inhibitor 1 (BAI1) is a pattern recognition receptor that mediates macrophage binding and engulfment of Gram ...
more infohttps://www.pnas.org/content/108/5/2136?ijkey=143e22d2a1c5586d22fa0e949faa79e5f810bbae&keytype2=tf_ipsecsha

BAIAP2L1 - Brain-specific angiogenesis inhibitor 1-associated protein 2-like protein 1 - Homo sapiens (Human) - BAIAP2L1 gene &...BAIAP2L1 - Brain-specific angiogenesis inhibitor 1-associated protein 2-like protein 1 - Homo sapiens (Human) - BAIAP2L1 gene &...

Brain-specific angiogenesis inhibitor 1-associated protein 2-like protein 1Add BLAST. 511. ... Brain-specific angiogenesis inhibitor 1-associated protein 2-like protein 1. ). MOUSE ... Brain-specific angiogenesis inhibitor 1-associated protein 2-like protein 1. RAT ... sp,Q9UHR4,BI2L1_HUMAN Brain-specific angiogenesis inhibitor 1-associated protein 2-like protein 1 OS=Homo sapiens OX=9606 GN= ...
more infohttps://www.uniprot.org/uniprot/Q9UHR4

Growth Factor and Angiogenesis Inhibitors |  OncologyPROGrowth Factor and Angiogenesis Inhibitors | OncologyPRO

PI3K inhibitors (BKM120, BYL19, PX-866), perifosine (PI3K and AKT inhibitor), and mTOR inhibitors (everolimus, temsirolimus) ... Growth Factor Angiogenesis Inhibitors Figure 1 - You do not have permission to view this object. ... Growth Factor Angiogenesis Inhibitors Figure 2 - You do not have permission to view this object. ... Growth Factor Angiogenesis Inhibitors Figure 3 - You do not have permission to view this object. ...
more infohttp://oncologypro.esmo.org/Education-Library/Essentials-for-Clinicians/Head-Neck-Cancers/Growth-Factor-and-Angiogenesis-Inhibitors
  • Angiogenesis inhibitors were once thought to have potential as a " silver bullet " treatment applicable to many types of cancer , but the limitations of anti-angiogenic therapy have been shown in practice. (wikipedia.org)
  • Nonetheless, inhibitors are used to effectively treat cancer, macular degeneration in the eye, and other diseases that involve a proliferation of blood vessels. (wikipedia.org)
  • Endogenous inhibitors are attractive targets for cancer therapy because they are less toxic and less likely to lead to drug resistance than some exogenous inhibitors. (wikipedia.org)
  • The Foundation promotes angiogenesis research and aiming to improve treatments for patients with angiogenesis related disease (including cancer). (cancerindex.org)
  • Angiogenesis inhibitors have different side effects from most conventional cancer chemotherapy medicines because they work very differently. (hopkinsmedicine.org)
  • Vitamin C therapy can down-regulate angiogenesis and inflammation promoting cytokines in some cancer patients. (greenmedinfo.com)
  • There is currently no reliable evidence from randomized controlled trials demonstrating that the benefits of angiogenesis-inhibitors outweigh their risks in treating advanced thyroid cancer. (cochrane.org)
  • There is currently no reliable evidence available from randomized controlled trials regarding the benefits and harms of the use of angiogenesis-inhibitors for treating advanced thyroid cancer. (cochrane.org)
  • To evaluate the benefits and risks of angiogenesis-inhibitors for metastatic thyroid cancer when given alone, or in combination with chemotherapy or radiotherapy. (cochrane.org)
  • We planned to include randomized controlled trials that compared angiogenesis-inhibitors with other treatments, no treatment, or placebo in participants who had pathologically confirmed advanced thyroid cancer. (cochrane.org)
  • Research in angiogenesis has strong implications in cancer therapy as angiogenesis is one of the hallmarks of cancer. (scbt.com)
  • Angiogenesis is an important therapeutic target in cancer, and to fully exploit its therapeutic potential, combination chemotherapeutic/antiangiogenic regimens should be optimized and delivered earlier to more patients. (aacrjournals.org)
  • Here, we present the effects of oral rifampicin on human cancer progression and its antiangiogenic properties, which were comparable to the angiogenesis inhibitor endostatin. (aacrjournals.org)
  • This phase I, accelerated titration study investigated the maximum tolerated dose, safety, pharmacokinetic profile, and pharmacodynamics of BIBF 1120, a novel, orally available angiokinase inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and fibroblast growth factor receptors, in 61 patients with advanced cancer. (aacrjournals.org)
  • Angiogenesis inhibitors offer a novel approach for cancer therapy ( 5 ). (aacrjournals.org)
  • Taken together, these findings clearly support the pharmacological roles of marmesin in regulating angiogenesis, and warrant further evaluation and development as a potential therapeutic agent for the treatment and prevention of angiogenesis-related diseases including cancer. (sigmaaldrich.com)
  • Angiogenesis inhibitors for the treatment of ovarian cancer. (ox.ac.uk)
  • OBJECTIVES: To compare the effectiveness and toxicities of angiogenesis inhibitors in the treatment of ovarian cancer. (ox.ac.uk)
  • We identified five abstracts of completed RCTs of four different angiogenesis-inhibiting agents, with a total of 3701 participants.Meta-analysis of two trials found no statistically significant difference in overall survival (OS) between women with newly-diagnosed advanced ovarian cancer who received concurrent and maintenance bevacizumab compared to those who received chemotherapy (carboplatin and paclitaxel) alone. (ox.ac.uk)
  • Cancer Angiogenesis Inhibitor Market Research Report Forecast 20172022 is a valuable source of insightful data for business strategists. (bioportfolio.com)
  • This Cancer Angiogenesis Inhibitor market study provides comprehensive data which enhances the understanding, scope and application of this report. (bioportfolio.com)
  • The side effects from angiogenesis inhibitors are generally less and milder than with conventional chemotherapy medicines. (hopkinsmedicine.org)
  • Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. (nih.gov)
  • Inhibiting angiogenesis requires treatment with anti-angiogenic factors, or drugs which reduce the production of pro-angiogenic factors, prevent them binding to their receptors or block their actions. (wikipedia.org)
  • An international peer-reviewed journal for original articles and reviews on the cellular and molecular mechanisms that regulate angiogenesis in physiological and pathological conditions. (cancerindex.org)
  • Thalidomide and lenalidomide have been identified as having mild activity as angiogenesis inhibitors. (hopkinsmedicine.org)
  • However, successful clinical application of angiogenesis inhibitors, irrespective of monotherapy or combination therapy, requires long-term administration, but most of these entering clinical trials are costly, large molecular weight proteins requiring parenteral administration ( 3 , 5 ). (aacrjournals.org)
  • We incorporated tumour growth, angiogenesis and vessel remodelling at tissue level, by coupling tumour cell phenotypes and endothelial cell behaviour in response to local chemical and haemodynamical microenvironment. (cancerindex.org)
  • competitive inhibitor of ATP in other protein kinase reactions. (sigmaaldrich.com)
  • The crystal structure of the human Pg-derived angiogenesis inhibitor, angiostatin, complexed to VEK-30, a peptide from the group A streptococcal surface protein, PAM, was determined and refined to 2.3 A resolution. (rcsb.org)
  • Recently, in our clinic, we found a number of patients, treated with oral angiogenesis inhibitors, a remarkable quickening of progressive disease and complaints after stopping this treatment. (clinicaltrials.gov)
  • This study means to gain more insight information about the optimal treatment policy when progressive disease is found in patients treated with oral angiogenesis inhibitors. (clinicaltrials.gov)